193 results on '"Vaccines, Combined therapeutic use"'
Search Results
2. Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults.
- Author
-
Lu Y, Matuska K, Nadimpalli G, Ma Y, Duma N, Zhang HT, Chiang Y, Lyu H, Chillarige Y, Kelman JA, Forshee RA, and Anderson SA
- Subjects
- Aged, Female, Humans, Male, 2019-nCoV Vaccine mRNA-1273 adverse effects, 2019-nCoV Vaccine mRNA-1273 therapeutic use, Adjuvants, Immunologic adverse effects, Adjuvants, Immunologic therapeutic use, BNT162 Vaccine adverse effects, BNT162 Vaccine therapeutic use, COVID-19 Vaccines adverse effects, COVID-19 Vaccines therapeutic use, Hemorrhagic Stroke chemically induced, Hemorrhagic Stroke epidemiology, Hemorrhagic Stroke etiology, Medicare, United States epidemiology, Vaccination adverse effects, Vaccination methods, Vaccines, Combined adverse effects, Vaccines, Combined therapeutic use, Centers for Disease Control and Prevention, U.S. statistics & numerical data, United States Food and Drug Administration statistics & numerical data, Aged, 80 and over, COVID-19 prevention & control, Influenza Vaccines adverse effects, Influenza Vaccines therapeutic use, Ischemic Attack, Transient chemically induced, Ischemic Attack, Transient epidemiology, Ischemic Attack, Transient etiology, Stroke epidemiology, Stroke etiology, Stroke prevention & control, Ischemic Stroke chemically induced, Ischemic Stroke epidemiology, Ischemic Stroke etiology, Influenza, Human prevention & control
- Abstract
Importance: In January 2023, the US Centers for Disease Control and Prevention and the US Food and Drug Administration noted a safety concern for ischemic stroke among adults aged 65 years or older who received the Pfizer-BioNTech BNT162b2; WT/OMI BA.4/BA.5 COVID-19 bivalent vaccine., Objective: To evaluate stroke risk after administration of (1) either brand of the COVID-19 bivalent vaccine, (2) either brand of the COVID-19 bivalent plus a high-dose or adjuvanted influenza vaccine on the same day (concomitant administration), and (3) a high-dose or adjuvanted influenza vaccine., Design, Setting, and Participants: Self-controlled case series including 11 001 Medicare beneficiaries aged 65 years or older who experienced stroke after receiving either brand of the COVID-19 bivalent vaccine (among 5 397 278 vaccinated individuals). The study period was August 31, 2022, through February 4, 2023., Exposures: Receipt of (1) either brand of the COVID-19 bivalent vaccine (primary) or (2) a high-dose or adjuvanted influenza vaccine (secondary)., Main Outcomes and Measures: Stroke risk (nonhemorrhagic stroke, transient ischemic attack, combined outcome of nonhemorrhagic stroke or transient ischemic attack, or hemorrhagic stroke) during the 1- to 21-day or 22- to 42-day risk window after vaccination vs the 43- to 90-day control window., Results: There were 5 397 278 Medicare beneficiaries who received either brand of the COVID-19 bivalent vaccine (median age, 74 years [IQR, 70-80 years]; 56% were women). Among the 11 001 beneficiaries who experienced stroke after receiving either brand of the COVID-19 bivalent vaccine, there were no statistically significant associations between either brand of the COVID-19 bivalent vaccine and the outcomes of nonhemorrhagic stroke, transient ischemic attack, nonhemorrhagic stroke or transient ischemic attack, or hemorrhagic stroke during the 1- to 21-day or 22- to 42-day risk window vs the 43- to 90-day control window (incidence rate ratio [IRR] range, 0.72-1.12). Among the 4596 beneficiaries who experienced stroke after concomitant administration of either brand of the COVID-19 bivalent vaccine plus a high-dose or adjuvanted influenza vaccine, there was a statistically significant association between vaccination and nonhemorrhagic stroke during the 22- to 42-day risk window for the Pfizer-BioNTech BNT162b2; WT/OMI BA.4/BA.5 COVID-19 bivalent vaccine (IRR, 1.20 [95% CI, 1.01-1.42]; risk difference/100 000 doses, 3.13 [95% CI, 0.05-6.22]) and a statistically significant association between vaccination and transient ischemic attack during the 1- to 21-day risk window for the Moderna mRNA-1273.222 COVID-19 bivalent vaccine (IRR, 1.35 [95% CI, 1.06-1.74]; risk difference/100 000 doses, 3.33 [95% CI, 0.46-6.20]). Among the 21 345 beneficiaries who experienced stroke after administration of a high-dose or adjuvanted influenza vaccine, there was a statistically significant association between vaccination and nonhemorrhagic stroke during the 22- to 42-day risk window (IRR, 1.09 [95% CI, 1.02-1.17]; risk difference/100 000 doses, 1.65 [95% CI, 0.43-2.87])., Conclusions and Relevance: Among Medicare beneficiaries aged 65 years or older who experienced stroke after receiving either brand of the COVID-19 bivalent vaccine, there was no evidence of a significantly elevated risk for stroke during the days immediately after vaccination.
- Published
- 2024
- Full Text
- View/download PDF
3. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
- Author
-
Feldstein LR, Britton A, Grant L, Wiegand R, Ruffin J, Babu TM, Briggs Hagen M, Burgess JL, Caban-Martinez AJ, Chu HY, Ellingson KD, Englund JA, Hegmann KT, Jeddy Z, Lauring AS, Lutrick K, Martin ET, Mathenge C, Meece J, Midgley CM, Monto AS, Newes-Adeyi G, Odame-Bamfo L, Olsho LEW, Phillips AL, Rai RP, Saydah S, Smith N, Steinhardt L, Tyner H, Vandermeer M, Vaughan M, Yoon SK, Gaglani M, and Naleway AL
- Subjects
- Adolescent, Child, Female, Humans, Male, Prospective Studies, SARS-CoV-2, mRNA Vaccines therapeutic use, Vaccines, Combined therapeutic use, Child, Preschool, Vaccine Efficacy, United States, COVID-19 diagnosis, COVID-19 prevention & control, COVID-19 Vaccines therapeutic use
- Abstract
Importance: Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022; however, data demonstrating the effectiveness of bivalent COVID-19 vaccines are limited., Objective: To assess the effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents., Design, Setting, and Participants: Data for the period September 4, 2022, to January 31, 2023, were combined from 3 prospective US cohort studies (6 sites total) and used to estimate COVID-19 vaccine effectiveness among children and adolescents aged 5 to 17 years. A total of 2959 participants completed periodic surveys (demographics, household characteristics, chronic medical conditions, and COVID-19 symptoms) and submitted weekly self-collected nasal swabs (irrespective of symptoms); participants submitted additional nasal swabs at the onset of any symptoms., Exposure: Vaccination status was captured from the periodic surveys and supplemented with data from state immunization information systems and electronic medical records., Main Outcome and Measures: Respiratory swabs were tested for the presence of the SARS-CoV-2 virus using reverse transcriptase-polymerase chain reaction. SARS-CoV-2 infection was defined as a positive test regardless of symptoms. Symptomatic COVID-19 was defined as a positive test and 2 or more COVID-19 symptoms within 7 days of specimen collection. Cox proportional hazards models were used to estimate hazard ratios for SARS-CoV-2 infection and symptomatic COVID-19 among participants who received a bivalent COVID-19 vaccine dose vs participants who received no vaccine or monovalent vaccine doses only. Models were adjusted for age, sex, race, ethnicity, underlying health conditions, prior SARS-CoV-2 infection status, geographic site, proportion of circulating variants by site, and local virus prevalence., Results: Of the 2959 participants (47.8% were female; median age, 10.6 years [IQR, 8.0-13.2 years]; 64.6% were non-Hispanic White) included in this analysis, 25.4% received a bivalent COVID-19 vaccine dose. During the study period, 426 participants (14.4%) had laboratory-confirmed SARS-CoV-2 infection. Among these 426 participants, 184 (43.2%) had symptomatic COVID-19, 383 (89.9%) were not vaccinated or had received only monovalent COVID-19 vaccine doses (1.38 SARS-CoV-2 infections per 1000 person-days), and 43 (10.1%) had received a bivalent COVID-19 vaccine dose (0.84 SARS-CoV-2 infections per 1000 person-days). Bivalent vaccine effectiveness against SARS-CoV-2 infection was 54.0% (95% CI, 36.6%-69.1%) and vaccine effectiveness against symptomatic COVID-19 was 49.4% (95% CI, 22.2%-70.7%). The median observation time after vaccination was 276 days (IQR, 142-350 days) for participants who received only monovalent COVID-19 vaccine doses vs 50 days (IQR, 27-74 days) for those who received a bivalent COVID-19 vaccine dose., Conclusion and Relevance: The bivalent COVID-19 vaccines protected children and adolescents against SARS-CoV-2 infection and symptomatic COVID-19. These data demonstrate the benefit of COVID-19 vaccine in children and adolescents. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations.
- Published
- 2024
- Full Text
- View/download PDF
4. Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age.
- Author
-
Hsiao A, Yee A, Fireman B, Hansen J, Lewis N, and Klein NP
- Subjects
- Adolescent, Adult, Humans, Middle Aged, Young Adult, Hospitalization, Proportional Hazards Models, Vaccines, Inactivated, Influenza Vaccines administration & dosage, Influenza Vaccines therapeutic use, Influenza, Human prevention & control, Influenza, Human epidemiology, Vaccines, Combined administration & dosage, Vaccines, Combined therapeutic use, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic therapeutic use
- Abstract
Background: Quadrivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard-dose egg-based vaccines, and the recombinant formulation is not susceptible to antigenic drift during manufacturing. Data are needed on the relative effectiveness of recombinant vaccines as compared with standard-dose vaccines against influenza-related outcomes in adults under the age of 65 years., Methods: In this cluster-randomized observational study, Kaiser Permanente Northern California facilities routinely administered either a high-dose recombinant influenza vaccine (Flublok Quadrivalent) or one of two standard-dose influenza vaccines during the 2018-2019 and 2019-2020 influenza seasons to adults 50 to 64 years of age (primary age group) and 18 to 49 years of age. Each facility alternated weekly between the two vaccine formulations. The primary outcome was influenza (A or B) confirmed by polymerase-chain-reaction (PCR) testing. Secondary outcomes included influenza A, influenza B, and influenza-related hospitalization outcomes. We used Cox regression analysis to estimate the hazard ratio of the recombinant vaccine as compared with the standard-dose vaccines against each outcome. We calculated the relative vaccine effectiveness as 1 minus the hazard ratio., Results: The study population included 1,630,328 vaccinees between the ages of 18 and 64 years (632,962 in the recombinant-vaccine group and 997,366 in the standard-dose group). During this study period, 1386 cases of PCR-confirmed influenza were diagnosed in the recombinant-vaccine group and 2435 cases in the standard-dose group. Among the participants who were 50 to 64 years of age, 559 participants (2.00 cases per 1000) tested positive for influenza in the recombinant-vaccine group as compared with 925 participants (2.34 cases per 1000) in the standard-dose group (relative vaccine effectiveness, 15.3%; 95% confidence interval [CI], 5.9 to 23.8; P = 0.002). In the same age group, the relative vaccine effectiveness against influenza A was 15.7% (95% CI, 6.0 to 24.5; P = 0.002). The recombinant vaccine was not significantly more protective against influenza-related hospitalization than were the standard-dose vaccines., Conclusions: The high-dose recombinant vaccine conferred more protection against PCR-confirmed influenza than an egg-based standard-dose vaccine among adults between the ages of 50 and 64 years. (Funded by Sanofi; ClinicalTrials.gov number, NCT03694392.)., (Copyright © 2023 Massachusetts Medical Society.)
- Published
- 2023
- Full Text
- View/download PDF
5. Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).
- Author
-
Pott H, Andrew MK, Shaffelburg Z, Nichols MK, Ye L, ElSherif M, Hatchette TF, LeBlanc J, Ambrose A, Boivin G, Bowie W, Johnstone J, Katz K, Lagacé-Wiens P, Loeb M, McCarthy A, McGeer A, Poirier A, Powis J, Richardson D, Semret M, Smith S, Smyth D, Stiver G, Trottier S, Valiquette L, Webster D, and McNeil SA
- Subjects
- Aged, Humans, Canada epidemiology, Hospitalization, Immunization, Seasons, Vaccines, Inactivated, Vaccines, Combined therapeutic use, Adjuvants, Immunologic, Frailty, Influenza Vaccines therapeutic use, Influenza, Human prevention & control, Influenza, Human epidemiology, Vaccine Efficacy
- Abstract
Background: Influenza vaccines prevent influenza-related morbidity and mortality; however, suboptimal vaccine effectiveness (VE) of non-adjuvanted trivalent inactivated influenza vaccine (naTIV) or quadrivalent formulations in older adults prompted the use of enhanced products such as adjuvanted TIV (aTIV). Here, the VE of aTIV is compared to naTIV for preventing influenza-associated hospitalization among older adults., Methods: A test-negative design study was used with pooled data from the 2012 to 2015 influenza seasons. An inverse probability of treatment (IPT)-weighted logistic regression estimated the Odds Ratio (OR) for laboratory-confirmed influenza-associated hospitalization. VE was calculated as (1-OR)*100% with accompanying 95% confidence intervals (CI)., Results: Of 7,101 adults aged ≥ 65, 3,364 received naTIV and 526 received aTIV. The overall VE against influenza hospitalization was 45.9% (95% CI: 40.2%-51.1%) for naTIV and 53.5% (42.8%-62.3%) for aTIV. No statistically significant differences in VE were found between aTIV and naTIV by age group or influenza season, though a trend favoring aTIV over naTIV was noted. Frailty may have impacted VE in aTIV recipients compared to those receiving naTIV, according to an exploratory analysis; VE adjusted by frailty was 59.1% (49.6%-66.8%) for aTIV and 44.8% (39.1%-50.0%) for naTIV. The overall relative VE of aTIV to naTIV against laboratory-confirmed influenza hospital admission was 25% (OR 0.75; 0.61-0.92), demonstrating statistically significant benefit favoring aTIV., Conclusions: Adjusting for frailty, aTIV showed statistically significantly better protection than naTIV against influenza-associated hospitalizations in older adults. In future studies, it is important to consider frailty as a significant confounder of VE., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: HP reports grant funding from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. MKA reports grant funding from the GSK group of companies, Pfizer and Sanofi Pasteur and honoraria from Sanofi, Seqirus and Pfizer for past ad hoc advisory activities. TFH reports grants from Pfizer and GSK, outside the submitted work. AMcG reports payments to her institution from the GSK group of companies for the conduct of this study, and payments from GSK, Seqirus and Sanofi Pasteur, outside the submitted work. ML reports payments from Sanofi, Medicago, Sequirus, and Pfizer outside the submitted work. AP reports payments from Actelion, Sanofi-Pasteur, and Genentech outside the submitted work. JP reports payments from the GSK group of companies, Merck, Roche, and Synthetic Biologics, outside the submitted work. MS reports payments from the GSK group of companies and Pfizer during the study. SAM reports grants and payments from Pfizer, GSK, Merck, Novartis and Sanofi, outside the submitted work. outside the submitted work. ZS, MKN, JJL, ME, GB, WB, PL-W, LV, GT, LY, AA, JJ, KK, DR, DW, DS, GS, ST, SS, AMcC and KK report no conflicts of interest., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
6. A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.
- Author
-
Chu K, Hu Y, Pan H, Wu J, Zhu D, Young MM Jr, Luo L, Yi Z, Giardina PC, Gruber WC, Scott DA, and Watson W
- Subjects
- Child, Child, Preschool, Humans, Infant, Antibodies, Bacterial, Immunoglobulin G, Streptococcus pneumoniae, Vaccines, Conjugate immunology, Vaccines, Conjugate therapeutic use, Treatment Outcome, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, East Asian People, Immunogenicity, Vaccine, Pneumococcal Infections prevention & control, Pneumococcal Vaccines immunology, Pneumococcal Vaccines therapeutic use
- Abstract
Streptococcus pneumoniae causes a considerable disease burden among children in China. Many isolates exhibit antimicrobial resistance but are often serotypes covered by the 13-valent pneumococcal conjugate vaccine (PCV13). Because the approved infant immunization schedule in China allows PCV13 vaccination only for those 6 weeks to 15 months of age, this phase 3 study was conducted to evaluate PCV13 immunogenicity and safety in unvaccinated older infants and children. Eligible participants were stratified by age into four cohorts: Cohort 1 ( n = 125), 6 weeks-2 months; Cohort 2 ( n = 354), 7-<12 months; Cohort 3 ( n = 250), 1 -<2 years; Cohort 4 ( n = 207), 2-<6 years. Cohort 1 received PCV13 at ages 2, 4, and 6 months; older cohorts were randomized 2:1 to PCV13 or Haemophilus influenzae type b (Hib) vaccine using age-appropriate schedules. Within-group immune responses were assessed by immunoglobulin G (IgG) concentrations and opsonophagocytic activity (OPA) titers. Safety evaluations included solicited reactogenicity events and adverse events (AEs). IgG geometric mean concentrations and OPA geometric mean titers for all 13 PCV13 serotypes increased for all participants vaccinated with PCV13, but not those vaccinated with Hib. Immune responses in Cohorts 2-4 were generally comparable with those in Cohort 1 (the infant series) for most serotypes. PCV13 was well tolerated across cohorts, with reported AEs consistent with expectations in these age groups; no new safety signals were identified. These results suggest that PCV13 administered as a catch-up regimen to infants and children 7 months-<6 years of age in China will effectively reduce vaccine-type pneumococcal disease in this population. NCT03574389.
- Published
- 2023
- Full Text
- View/download PDF
7. Potential for Maternally Administered Vaccine for Infant Group B Streptococcus.
- Author
-
Madhi SA, Anderson AS, Absalon J, Radley D, Simon R, Jongihlati B, Strehlau R, van Niekerk AM, Izu A, Naidoo N, Kwatra G, Ramsamy Y, Said M, Jones S, Jose L, Fairlie L, Barnabas SL, Newton R, Munson S, Jefferies Z, Pavliakova D, Silmon de Monerri NC, Gomme E, Perez JL, Scott DA, Gruber WC, and Jansen KU
- Subjects
- Female, Humans, Infant, Infant, Newborn, Pregnancy, Antibodies, Bacterial, Immunoglobulin G, Seroepidemiologic Studies, Vaccines, Combined administration & dosage, Vaccines, Combined adverse effects, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, Vaccines, Conjugate administration & dosage, Vaccines, Conjugate adverse effects, Vaccines, Conjugate immunology, Vaccines, Conjugate therapeutic use, Immunity, Maternally-Acquired immunology, Streptococcal Infections epidemiology, Streptococcal Infections immunology, Streptococcal Infections prevention & control, Streptococcus agalactiae, Streptococcal Vaccines administration & dosage, Streptococcal Vaccines adverse effects, Streptococcal Vaccines immunology, Streptococcal Vaccines therapeutic use
- Abstract
Background: Natural history studies have correlated serotype-specific anti-capsular polysaccharide (CPS) IgG in newborns with a reduced risk of group B streptococcal disease. A hexavalent CPS-cross-reactive material 197 glycoconjugate vaccine (GBS6) is being developed as a maternal vaccine to prevent invasive group B streptococcus in young infants., Methods: In an ongoing phase 2, placebo-controlled trial involving pregnant women, we assessed the safety and immunogenicity of a single dose of various GBS6 formulations and analyzed maternally transferred anti-CPS antibodies. In a parallel seroepidemiologic study that was conducted in the same population, we assessed serotype-specific anti-CPS IgG concentrations that were associated with a reduced risk of invasive disease among newborns through 89 days of age to define putative protective thresholds., Results: Naturally acquired anti-CPS IgG concentrations were associated with a reduced risk of disease among infants in the seroepidemiologic study. IgG thresholds that were determined to be associated with 75 to 95% reductions in the risk of disease were 0.184 to 0.827 μg per milliliter. No GBS6-associated safety signals were observed among the mothers or infants. The incidence of adverse events and of serious adverse events were similar across the trial groups for both mothers and infants; more local reactions were observed in the groups that received GBS6 containing aluminum phosphate. Among the infants, the most common serious adverse events were minor congenital anomalies (umbilical hernia and congenital dermal melanocytosis). GBS6 induced maternal antibody responses to all serotypes, with maternal-to-infant antibody ratios of approximately 0.4 to 1.3, depending on the dose. The percentage of infants with anti-CPS IgG concentrations above 0.184 μg per milliliter varied according to serotype and formulation, with 57 to 97% of the infants having a seroresponse to the most immunogenic formulation., Conclusions: GBS6 elicited anti-CPS antibodies against group B streptococcus in pregnant women that were transferred to infants at levels associated with a reduced risk of invasive group B streptococcal disease. (Funded by Pfizer and the Bill and Melinda Gates Foundation; C1091002 ClinicalTrials.gov number, NCT03765073.)., (Copyright © 2023 Massachusetts Medical Society.)
- Published
- 2023
- Full Text
- View/download PDF
8. BA.1 Bivalent COVID-19 Vaccine Use and Stroke in England.
- Author
-
Andrews N, Stowe J, Miller E, and Ramsay M
- Subjects
- Humans, Influenza Vaccines therapeutic use, Influenza, Human prevention & control, Vaccination adverse effects, England epidemiology, Vaccines, Combined adverse effects, Vaccines, Combined therapeutic use, COVID-19 epidemiology, COVID-19 prevention & control, COVID-19 virology, COVID-19 Vaccines adverse effects, COVID-19 Vaccines therapeutic use, Stroke epidemiology, Stroke etiology
- Published
- 2023
- Full Text
- View/download PDF
9. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
- Author
-
Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, Rämet M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, and Schmoele-Thoma B
- Subjects
- Aged, Humans, Antibodies, Viral, Double-Blind Method, Vaccines, Combined administration & dosage, Vaccines, Combined adverse effects, Vaccines, Combined therapeutic use, Vaccine Efficacy, Treatment Outcome, Middle Aged, Injections, Intramuscular, Respiratory Syncytial Virus Infections diagnosis, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Vaccines administration & dosage, Respiratory Syncytial Virus Vaccines adverse effects, Respiratory Syncytial Virus Vaccines therapeutic use, Respiratory Tract Infections diagnosis, Respiratory Tract Infections epidemiology, Respiratory Tract Infections prevention & control
- Abstract
Background: Respiratory syncytial virus (RSV) infection causes considerable illness in older adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein-based (RSVpreF) vaccine in this population are unknown., Methods: In this ongoing, phase 3 trial, we randomly assigned, in a 1:1 ratio, adults (≥60 years of age) to receive a single intramuscular injection of RSVpreF vaccine at a dose of 120 μg (RSV subgroups A and B, 60 μg each) or placebo. The two primary end points were vaccine efficacy against seasonal RSV-associated lower respiratory tract illness with at least two or at least three signs or symptoms. The secondary end point was vaccine efficacy against RSV-associated acute respiratory illness., Results: At the interim analysis (data-cutoff date, July 14, 2022), 34,284 participants had received RSVpreF vaccine (17,215 participants) or placebo (17,069 participants). RSV-associated lower respiratory tract illness with at least two signs or symptoms occurred in 11 participants in the vaccine group (1.19 cases per 1000 person-years of observation) and 33 participants in the placebo group (3.58 cases per 1000 person-years of observation) (vaccine efficacy, 66.7%; 96.66% confidence interval [CI], 28.8 to 85.8); 2 cases (0.22 cases per 1000 person-years of observation) and 14 cases (1.52 cases per 1000 person-years of observation), respectively, occurred with at least three signs or symptoms (vaccine efficacy, 85.7%; 96.66% CI, 32.0 to 98.7). RSV-associated acute respiratory illness occurred in 22 participants in the vaccine group (2.38 cases per 1000 person-years of observation) and 58 participants in the placebo group (6.30 cases per 1000 person-years of observation) (vaccine efficacy, 62.1%; 95% CI, 37.1 to 77.9). The incidence of local reactions was higher with vaccine (12%) than with placebo (7%); the incidences of systemic events were similar (27% and 26%, respectively). Similar rates of adverse events through 1 month after injection were reported (vaccine, 9.0%; placebo, 8.5%), with 1.4% and 1.0%, respectively, considered by the investigators to be injection-related. Severe or life-threatening adverse events were reported in 0.5% of vaccine recipients and 0.4% of placebo recipients. Serious adverse events were reported in 2.3% of participants in each group through the data-cutoff date., Conclusions: RSVpreF vaccine prevented RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults (≥60 years of age), without evident safety concerns. (Funded by Pfizer; RENOIR ClinicalTrials.gov number, NCT05035212; EudraCT number, 2021-003693-31.)., (Copyright © 2023 Massachusetts Medical Society.)
- Published
- 2023
- Full Text
- View/download PDF
10. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
- Author
-
Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, Glanternik J, Snaggs H, Baber J, Zachariah P, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Duron Padilla M, Richmond PC, Koury K, Schneider K, Kalinina EV, Cooper D, Jansen KU, Anderson AS, Swanson KA, Gruber WC, and Gurtman A
- Subjects
- Female, Humans, Infant, Infant, Newborn, Pregnancy, Antibodies, Viral, Communicable Diseases therapy, Double-Blind Method, Injections, Intramuscular, Respiratory Syncytial Viruses, Treatment Outcome, Vaccination adverse effects, Vaccination methods, Vaccine Efficacy, Vaccines, Combined administration & dosage, Vaccines, Combined adverse effects, Vaccines, Combined therapeutic use, Respiratory Syncytial Virus Infections epidemiology, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus Vaccines administration & dosage, Respiratory Syncytial Virus Vaccines adverse effects, Respiratory Syncytial Virus Vaccines therapeutic use, Respiratory Tract Infections epidemiology, Respiratory Tract Infections prevention & control
- Abstract
Background: Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain., Methods: In this phase 3, double-blind trial conducted in 18 countries, we randomly assigned, in a 1:1 ratio, pregnant women at 24 through 36 weeks' gestation to receive a single intramuscular injection of 120 μg of a bivalent RSV prefusion F protein-based (RSVpreF) vaccine or placebo. The two primary efficacy end points were medically attended severe RSV-associated lower respiratory tract illness and medically attended RSV-associated lower respiratory tract illness in infants within 90, 120, 150, and 180 days after birth. A lower boundary of the confidence interval for vaccine efficacy (99.5% confidence interval [CI] at 90 days; 97.58% CI at later intervals) greater than 20% was considered to meet the success criterion for vaccine efficacy with respect to the primary end points., Results: At this prespecified interim analysis, the success criterion for vaccine efficacy was met with respect to one primary end point. Overall, 3682 maternal participants received vaccine and 3676 received placebo; 3570 and 3558 infants, respectively, were evaluated. Medically attended severe lower respiratory tract illness occurred within 90 days after birth in 6 infants of women in the vaccine group and 33 infants of women in the placebo group (vaccine efficacy, 81.8%; 99.5% CI, 40.6 to 96.3); 19 cases and 62 cases, respectively, occurred within 180 days after birth (vaccine efficacy, 69.4%; 97.58% CI, 44.3 to 84.1). Medically attended RSV-associated lower respiratory tract illness occurred within 90 days after birth in 24 infants of women in the vaccine group and 56 infants of women in the placebo group (vaccine efficacy, 57.1%; 99.5% CI, 14.7 to 79.8); these results did not meet the statistical success criterion. No safety signals were detected in maternal participants or in infants and toddlers up to 24 months of age. The incidences of adverse events reported within 1 month after injection or within 1 month after birth were similar in the vaccine group (13.8% of women and 37.1% of infants) and the placebo group (13.1% and 34.5%, respectively)., Conclusions: RSVpreF vaccine administered during pregnancy was effective against medically attended severe RSV-associated lower respiratory tract illness in infants, and no safety concerns were identified. (Funded by Pfizer; MATISSE ClinicalTrials.gov number, NCT04424316.)., (Copyright © 2023 Massachusetts Medical Society.)
- Published
- 2023
- Full Text
- View/download PDF
11. Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster.
- Author
-
Jabagi MJ, Bertrand M, Botton J, Le Vu S, Weill A, Dray-Spira R, and Zureik M
- Subjects
- Humans, COVID-19 prevention & control, Myocardial Infarction chemically induced, Myocardial Infarction etiology, Pulmonary Embolism chemically induced, Pulmonary Embolism diagnostic imaging, Pulmonary Embolism etiology, Stroke chemically induced, Stroke etiology, Cardiovascular Diseases chemically induced, Cardiovascular Diseases diagnostic imaging, Cardiovascular Diseases etiology, COVID-19 Vaccines adverse effects, COVID-19 Vaccines therapeutic use, Immunization, Secondary adverse effects, Vaccines, Combined adverse effects, Vaccines, Combined therapeutic use
- Published
- 2023
- Full Text
- View/download PDF
12. Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis.
- Author
-
Huth L, Schäfer L, Almanzar G, Lupoli G, Bischof M, Wratil PR, Stövesand T, Drechsler C, Keppler OT, and Prelog M
- Subjects
- Humans, Immunogenicity, Vaccine immunology, Immunization, Secondary adverse effects, Immunization, Secondary methods, Renal Dialysis, Kidney Failure, Chronic complications, Kidney Failure, Chronic immunology, Kidney Failure, Chronic therapy, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, COVID-19 Vaccines immunology, COVID-19 Vaccines therapeutic use, COVID-19 complications, COVID-19 immunology, COVID-19 prevention & control
- Published
- 2023
- Full Text
- View/download PDF
13. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.
- Author
-
Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M, Cooper D, Yang Q, Cai H, Muik A, Zhang Y, Lee DY, Şahin U, Anderson AS, Gruber WC, Xie X, Swanson KA, and Shi PY
- Subjects
- Humans, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, SARS-CoV-2 immunology, COVID-19 immunology, COVID-19 therapy, COVID-19 virology, COVID-19 Vaccines immunology, COVID-19 Vaccines therapeutic use
- Published
- 2023
- Full Text
- View/download PDF
14. Bivalent Covid-19 Vaccines - A Cautionary Tale.
- Author
-
Offit PA
- Subjects
- Humans, SARS-CoV-2, COVID-19 prevention & control, COVID-19 Vaccines adverse effects, COVID-19 Vaccines therapeutic use, Vaccines, Combined adverse effects, Vaccines, Combined therapeutic use
- Published
- 2023
- Full Text
- View/download PDF
15. Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.
- Author
-
Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, Gallup L, Rowe M, Schonberg E, Thai S, Barrett J, Borducchi EN, Bouffard E, Jacob-Dolan C, Mazurek CR, Mutoni A, Powers O, Sciacca M, Surve N, VanWyk H, Wu C, and Barouch DH
- Subjects
- Humans, Antibodies, Neutralizing, Antibodies, Viral, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, Vaccines, Synthetic immunology, Vaccines, Synthetic therapeutic use, mRNA Vaccines, Immunogenicity, Vaccine immunology, COVID-19 genetics, COVID-19 immunology, COVID-19 prevention & control, COVID-19 virology
- Published
- 2023
- Full Text
- View/download PDF
16. Antibody Response to Omicron BA.4-BA.5 Bivalent Booster.
- Author
-
Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L, and Ho DD
- Subjects
- Humans, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Antibody Formation immunology, COVID-19 immunology, COVID-19 prevention & control, COVID-19 virology
- Published
- 2023
- Full Text
- View/download PDF
17. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
- Author
-
Winokur P, Gayed J, Fitz-Patrick D, Thomas SJ, Diya O, Lockhart S, Xu X, Zhang Y, Bangad V, Schwartz HI, Denham D, Cardona JF, Usdan L, Ginis J, Mensa FJ, Zou J, Xie X, Shi PY, Lu C, Buitrago S, Scully IL, Cooper D, Koury K, Jansen KU, Türeci Ö, Şahin U, Swanson KA, Gruber WC, and Kitchin N
- Subjects
- Humans, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Vaccination, Middle Aged, BNT162 Vaccine adverse effects, BNT162 Vaccine immunology, BNT162 Vaccine therapeutic use, COVID-19 genetics, COVID-19 immunology, COVID-19 prevention & control, COVID-19 virology, SARS-CoV-2 drug effects, SARS-CoV-2 genetics, SARS-CoV-2 immunology, Vaccines, Combined therapeutic use
- Abstract
Background: The emergence of immune-escape variants of severe acute respiratory syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection against coronavirus disease 2019., Methods: In an ongoing phase 3 trial, adults older than 55 years who had previously received three 30-μg doses of the BNT162b2 vaccine were randomly assigned to receive 30 μg or 60 μg of BNT162b2, 30 μg or 60 μg of monovalent B.1.1.529 (omicron) BA.1-adapted BNT162b2 (monovalent BA.1), or 30 μg (15 μg of BNT162b2 + 15 μg of monovalent BA.1) or 60 μg (30 μg of BNT162b2 + 30 μg of monovalent BA.1) of BA.1-adapted BNT162b2 (bivalent BA.1). Primary objectives were to determine superiority (with respect to 50% neutralizing titer [NT
50 ] against BA.1) and noninferiority (with respect to seroresponse) of the BA.1-adapted vaccines to BNT162b2 (30 μg). A secondary objective was to determine noninferiority of bivalent BA.1 to BNT162b2 (30 μg) with respect to neutralizing activity against the ancestral strain. Exploratory analyses assessed immune responses against omicron BA.4, BA.5, and BA.2.75 subvariants., Results: A total of 1846 participants underwent randomization. At 1 month after vaccination, bivalent BA.1 (30 μg and 60 μg) and monovalent BA.1 (60 μg) showed neutralizing activity against BA.1 superior to that of BNT162b2 (30 μg), with NT50 geometric mean ratios (GMRs) of 1.56 (95% confidence interval [CI], 1.17 to 2.08), 1.97 (95% CI, 1.45 to 2.68), and 3.15 (95% CI, 2.38 to 4.16), respectively. Bivalent BA.1 (both doses) and monovalent BA.1 (60 μg) were also noninferior to BNT162b2 (30 μg) with respect to seroresponse against BA.1; between-group differences ranged from 10.9 to 29.1 percentage points. Bivalent BA.1 (either dose) was noninferior to BNT162b2 (30 μg) with respect to neutralizing activity against the ancestral strain, with NT50 GMRs of 0.99 (95% CI, 0.82 to 1.20) and 1.30 (95% CI, 1.07 to 1.58), respectively. BA.4-BA.5 and BA.2.75 neutralizing titers were numerically higher with 30-μg bivalent BA.1 than with 30-μg BNT162b2. The safety profile of either dose of monovalent or bivalent BA.1 was similar to that of BNT162b2 (30 μg). Adverse events were more common in the 30-μg monovalent-BA.1 (8.5%) and 60-μg bivalent-BA.1 (10.4%) groups than in the other groups (3.6 to 6.6%)., Conclusions: The candidate monovalent or bivalent omicron BA.1-adapted vaccines had a safety profile similar to that of BNT162b2 (30 μg), induced substantial neutralizing responses against ancestral and omicron BA.1 strains, and, to a lesser extent, neutralized BA.4, BA.5, and BA.2.75 strains. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04955626.)., (Copyright © 2023 Massachusetts Medical Society.)- Published
- 2023
- Full Text
- View/download PDF
18. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
- Author
-
Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, Sutherland A, Montefiori DC, Girard B, Edwards DK, Feng J, Zhou H, Baden LR, Miller JM, and Das R
- Subjects
- 2019-nCoV Vaccine mRNA-1273 immunology, 2019-nCoV Vaccine mRNA-1273 therapeutic use, Adult, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Humans, Immunogenicity, Vaccine immunology, SARS-CoV-2, COVID-19 immunology, COVID-19 prevention & control, COVID-19 Vaccines immunology, COVID-19 Vaccines therapeutic use, Immunization, Secondary, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, mRNA Vaccines immunology, mRNA Vaccines therapeutic use
- Abstract
Background: The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known., Methods: In this ongoing, phase 2-3 study, we compared the 50-μg bivalent vaccine mRNA-1273.214 (25 μg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 [BA.1] spike messenger RNAs) with the previously authorized 50-μg mRNA-1273 booster. We administered mRNA-1273.214 or mRNA-1273 as a second booster in adults who had previously received a two-dose (100-μg) primary series and first booster (50-μg) dose of mRNA-1273 (≥3 months earlier). The primary objectives were to assess the safety, reactogenicity, and immunogenicity of mRNA-1273.214 at 28 days after the booster dose., Results: Interim results are presented. Sequential groups of participants received 50 μg of mRNA-1273.214 (437 participants) or mRNA-1273 (377 participants) as a second booster dose. The median time between the first and second boosters was similar for mRNA-1273.214 (136 days) and mRNA-1273 (134 days). In participants with no previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the geometric mean titers of neutralizing antibodies against the omicron BA.1 variant were 2372.4 (95% confidence interval [CI], 2070.6 to 2718.2) after receipt of the mRNA-1273.214 booster and 1473.5 (95% CI, 1270.8 to 1708.4) after receipt of the mRNA-1273 booster. In addition, 50-μg mRNA-1273.214 and 50-μg mRNA-1273 elicited geometric mean titers of 727.4 (95% CI, 632.8 to 836.1) and 492.1 (95% CI, 431.1 to 561.9), respectively, against omicron BA.4 and BA.5 (BA.4/5), and the mRNA-1273.214 booster also elicited higher binding antibody responses against multiple other variants (alpha, beta, gamma, and delta) than the mRNA-1273 booster. Safety and reactogenicity were similar with the two booster vaccines. Vaccine effectiveness was not assessed in this study; in an exploratory analysis, SARS-CoV-2 infection occurred in 11 participants after the mRNA-1273.214 booster and in 9 participants after the mRNA-1273 booster., Conclusions: The bivalent omicron-containing vaccine mRNA-1273.214 elicited neutralizing antibody responses against omicron that were superior to those with mRNA-1273, without evident safety concerns. (Funded by Moderna; ClinicalTrials.gov number, NCT04927065.)., (Copyright © 2022 Massachusetts Medical Society.)
- Published
- 2022
- Full Text
- View/download PDF
19. Audio Interview: Assessing Bivalent Vaccines against Covid-19.
- Author
-
Rubin EJ, Baden LR, and Morrissey S
- Subjects
- Humans, Viral Vaccines therapeutic use, COVID-19 prevention & control, COVID-19 Vaccines therapeutic use, Vaccines, Combined therapeutic use
- Published
- 2022
- Full Text
- View/download PDF
20. New Data on Heterologous COVID-19 Vaccine Combinations.
- Author
-
Larkin HD
- Subjects
- Antibodies, Viral, Humans, COVID-19 prevention & control, COVID-19 Vaccines, Influenza Vaccines, Vaccines, Combined therapeutic use
- Published
- 2022
- Full Text
- View/download PDF
21. Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice.
- Author
-
Dzul-Huchim VM, Ramirez-Sierra MJ, Martinez-Vega PP, Rosado-Vallado ME, Arana-Argaez VE, Ortega-Lopez J, Gusovsky F, Dumonteil E, Cruz-Chan JV, Hotez P, Bottazzi ME, and Villanueva-Lizama LE
- Subjects
- Adjuvants, Immunologic, Animals, Dogs, Fibrosis, Humans, Inflammation drug therapy, Mice, Mice, Inbred BALB C, Nitroimidazoles, Perforin, Recombinant Proteins, Toll-Like Receptor 4, Vaccines, Combined therapeutic use, Chagas Disease drug therapy, Protozoan Vaccines, Trypanosoma cruzi genetics, Vaccines, DNA
- Abstract
Background: Chagas disease (CD) is caused by Trypanosoma cruzi and affects 6-7 million people worldwide. Approximately 30% of chronic patients develop chronic chagasic cardiomyopathy (CCC) after decades. Benznidazole (BNZ), one of the first-line chemotherapy used for CD, induces toxicity and fails to halt the progression of CCC in chronic patients. The recombinant parasite-derived antigens, including Tc24, Tc24-C4, TSA-1, and TSA-1-C4 with Toll-like receptor 4 (TLR-4) agonist-adjuvants reduce cardiac parasite burdens, heart inflammation, and fibrosis, leading us to envision their use as immunotherapy together with BNZ. Given genetic immunization (DNA vaccines) encoding Tc24 and TSA-1 induce protective immunity in mice and dogs, we propose that immunization with the corresponding recombinant proteins offers an alternative and feasible strategy to develop these antigens as a bivalent human vaccine. We hypothesized that a low dose of BNZ in combination with a therapeutic vaccine (TSA-1-C4 and Tc24-C4 antigens formulated with a synthetic TLR-4 agonist-adjuvant, E6020-SE) given during early chronic infection, could prevent cardiac disease progression and provide antigen-specific T cell immunity., Methodology/ Principal Findings: We evaluated the therapeutic vaccine candidate plus BNZ (25 mg/kg/day/7 days) given on days 72 and 79 post-infection (p.i) (early chronic phase). Fibrosis, inflammation, and parasite burden were quantified in heart tissue at day 200 p.i. (late chronic phase). Further, spleen cells were collected to evaluate antigen-specific CD4+ and CD8+ T cell immune response, using flow cytometry. We found that vaccine-linked BNZ treated mice had lower cardiac fibrosis compared to the infected untreated control group. Moreover, cells from mice that received the immunotherapy had higher stimulation index of antigen-specific CD8+Perforin+ T cells as well as antigen-specific central memory T cells compared to the infected untreated control., Conclusions: Our results suggest that the bivalent immunotherapy together with BNZ treatment given during early chronic infection protects BALB/c mice against cardiac fibrosis progression and activates a strong CD8+ T cell response by in vitro restimulation, evidencing the induction of a long-lasting T. cruzi-immunity., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: María Elena Bottazzi and Peter J. Hotez are part of a team of scientists advancing research towards the development of a therapeutic Chagas disease vaccine and are listed among the inventors on Chagas disease vaccine patents submitted by Baylor College of Medicine and others. Author Fabian Gusovsky is employed by Eisai, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
22. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.
- Author
-
Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, and Fry AM
- Subjects
- Adult, Advisory Committees, Child, Female, Humans, Immunization Schedule, Infant, Influenza A Virus, H3N2 Subtype, Influenza B virus, Pregnancy, Seasons, United States epidemiology, Vaccination, Vaccines, Combined therapeutic use, Vaccines, Inactivated therapeutic use, Influenza A Virus, H1N1 Subtype, Influenza Vaccines therapeutic use, Influenza, Human epidemiology, Influenza, Human prevention & control
- Abstract
THIS REPORT UPDATES THE 2021-22 RECOMMENDATIONS OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) CONCERNING THE USE OF SEASONAL INFLUENZA VACCINES IN THE UNITED STATES: (MMWR Recomm Rep 2021;70[No. RR-5]:1-24). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. With the exception of vaccination for adults aged ≥65 years, ACIP makes no preferential recommendation for a specific vaccine when more than one licensed, recommended, and age-appropriate vaccine is available. All seasonal influenza vaccines expected to be available in the United States for the 2022-23 season are quadrivalent, containing hemagglutinin (HA) derived from one influenza A(H1N1)pdm09 virus, one influenza A(H3N2) virus, one influenza B/Victoria lineage virus, and one influenza B/Yamagata lineage virus. Inactivated influenza vaccines (IIV4s), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Trivalent influenza vaccines are no longer available, but data that involve these vaccines are included for reference. INFLUENZA VACCINES MIGHT BE AVAILABLE AS EARLY AS JULY OR AUGUST, BUT FOR MOST PERSONS WHO NEED ONLY 1 DOSE OF INFLUENZA VACCINE FOR THE SEASON, VACCINATION SHOULD IDEALLY BE OFFERED DURING SEPTEMBER OR OCTOBER. HOWEVER, VACCINATION SHOULD CONTINUE AFTER OCTOBER AND THROUGHOUT THE SEASON AS LONG AS INFLUENZA VIRUSES ARE CIRCULATING AND UNEXPIRED VACCINE IS AVAILABLE. FOR MOST ADULTS (PARTICULARLY ADULTS AGED ≥65 YEARS) AND FOR PREGNANT PERSONS IN THE FIRST OR SECOND TRIMESTER, VACCINATION DURING JULY AND AUGUST SHOULD BE AVOIDED UNLESS THERE IS CONCERN THAT VACCINATION LATER IN THE SEASON MIGHT NOT BE POSSIBLE. CERTAIN CHILDREN AGED 6 MONTHS THROUGH 8 YEARS NEED 2 DOSES; THESE CHILDREN SHOULD RECEIVE THE FIRST DOSE AS SOON AS POSSIBLE AFTER VACCINE IS AVAILABLE, INCLUDING DURING JULY AND AUGUST. VACCINATION DURING JULY AND AUGUST CAN BE CONSIDERED FOR CHILDREN OF ANY AGE WHO NEED ONLY 1 DOSE FOR THE SEASON AND FOR PREGNANT PERSONS WHO ARE IN THE THIRD TRIMESTER IF VACCINE IS AVAILABLE DURING THOSE MONTHS: UPDATES DESCRIBED IN THIS REPORT REFLECT DISCUSSIONS DURING PUBLIC MEETINGS OF ACIP THAT WERE HELD ON OCTOBER 20, 2021; JANUARY 12, 2022; FEBRUARY 23, 2022; AND JUNE 22, 2022. PRIMARY UPDATES TO THIS REPORT INCLUDE THE FOLLOWING THREE TOPICS: 1) THE COMPOSITION OF 2022-23 U.S. SEASONAL INFLUENZA VACCINES; 2) UPDATES TO THE DESCRIPTION OF INFLUENZA VACCINES EXPECTED TO BE AVAILABLE FOR THE 2022-23 SEASON, INCLUDING ONE INFLUENZA VACCINE LABELING CHANGE THAT OCCURRED AFTER THE PUBLICATION OF THE 2021-22 ACIP INFLUENZA RECOMMENDATIONS; AND 3) UPDATES TO THE RECOMMENDATIONS CONCERNING VACCINATION OF ADULTS AGED ≥65 YEARS. FIRST, THE COMPOSITION OF 2022-23 U.S. INFLUENZA VACCINES INCLUDES UPDATES TO THE INFLUENZA A(H3N2) AND INFLUENZA B/VICTORIA LINEAGE COMPONENTS. U.S.-LICENSED INFLUENZA VACCINES WILL CONTAIN HA DERIVED FROM AN INFLUENZA A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE VIRUS (FOR EGG-BASED VACCINES) OR AN INFLUENZA A/WISCONSIN/588/2019 (H1N1)PDM09-LIKE VIRUS (FOR CELL CULTURE-BASED OR RECOMBINANT VACCINES); AN INFLUENZA A/DARWIN/9/2021 (H3N2)-LIKE VIRUS (FOR EGG-BASED VACCINES) OR AN INFLUENZA A/DARWIN/6/2021 (H3N2)-LIKE VIRUS (FOR CELL CULTURE-BASED OR RECOMBINANT VACCINES); AN INFLUENZA B/AUSTRIA/1359417/2021 (VICTORIA LINEAGE)-LIKE VIRUS; AND AN INFLUENZA B/PHUKET/3073/2013 (YAMAGATA LINEAGE)-LIKE VIRUS. SECOND, THE APPROVED AGE INDICATION FOR THE CELL CULTURE-BASED INACTIVATED INFLUENZA VACCINE, FLUCELVAX QUADRIVALENT (CCIIV4), WAS CHANGED IN OCTOBER 2021 FROM ≥2 YEARS TO ≥6 MONTHS. THIRD, RECOMMENDATIONS FOR VACCINATION OF ADULTS AGED ≥65 YEARS HAVE BEEN MODIFIED. ACIP RECOMMENDS THAT ADULTS AGED ≥65 YEARS PREFERENTIALLY RECEIVE ANY ONE OF THE FOLLOWING HIGHER DOSE OR ADJUVANTED INFLUENZA VACCINES: QUADRIVALENT HIGH-DOSE INACTIVATED INFLUENZA VACCINE (HD-IIV4), QUADRIVALENT RECOMBINANT INFLUENZA VACCINE (RIV4), OR QUADRIVALENT ADJUVANTED INACTIVATED INFLUENZA VACCINE (AIIV4). IF NONE OF THESE THREE VACCINES IS AVAILABLE AT AN OPPORTUNITY FOR VACCINE ADMINISTRATION, THEN ANY OTHER AGE-APPROPRIATE INFLUENZA VACCINE SHOULD BE USED: THIS REPORT FOCUSES ON RECOMMENDATIONS FOR THE USE OF VACCINES FOR THE PREVENTION AND CONTROL OF SEASONAL INFLUENZA DURING THE 2022-23 INFLUENZA SEASON IN THE UNITED STATES. A BRIEF SUMMARY OF THE RECOMMENDATIONS AND A LINK TO THE MOST RECENT BACKGROUND DOCUMENT CONTAINING ADDITIONAL INFORMATION ARE AVAILABLE AT: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to U.S.-licensed influenza vaccines used according to Food and Drug Administration-licensed indications. Updates and other information are available from CDC's influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check this site periodically for additional information., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for the disclosure of potential conflicts of interest. Helen Keipp Talbot reports receiving financial support from CDC. No other potential conflicts of interest were disclosed. This report includes discussion of the unlabeled use of influenza vaccines in the instance of influenza vaccination of persons with a history of egg allergy. A history of severe allergic reaction (e.g., anaphylaxis) to the vaccine or any of its components (which include egg for certain vaccines) is a labeled contraindication to receipt of most IIV4s and LAIV4. However, ACIP recommends that persons with a history of allergic reaction of any severity to egg should receive any licensed, recommended influenza vaccine that is appropriate for their age and health status. Persons with a history of severe allergic reaction to egg who receive egg-based vaccines (i.e., vaccines other than cell culture–based inactivated influenza vaccine [ccIIV4] or recombinant influenza vaccine [RIV4]) should be vaccinated in an inpatient or outpatient medical setting (including, but not necessarily limited to, hospitals, clinics, health departments, and physician offices); vaccine administration in such instances should be supervised by a health care provider who is able to recognize and manage severe allergic reactions. No postvaccination waiting period is recommended specifically for egg-allergic persons. However, ACIP recommends that vaccine providers consider observing patients seated or supine for 15 minutes after administration of any vaccine (regardless of allergy history) to decrease the risk for injury should syncope occur.
- Published
- 2022
- Full Text
- View/download PDF
23. Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study.
- Author
-
Shimakawa Y, Veillon P, Birguel J, Pivert A, Sauvage V, Guillou-Guillemette HL, Roger S, Njouom R, Ducancelle A, Amta P, Huraux JM, Adoukara JP, and Lunel-Fabiani F
- Subjects
- Antiviral Agents therapeutic use, Cameroon epidemiology, DNA, Viral, Female, Hepatitis B Surface Antigens, Hepatitis B Vaccines, Hepatitis B virus, Humans, Infectious Disease Transmission, Vertical prevention & control, Pregnancy, Vaccination, Vaccines, Combined therapeutic use, Hepatitis B drug therapy, Hepatitis B epidemiology, Hepatitis B prevention & control, Pregnancy Complications, Infectious drug therapy, Pregnancy Complications, Infectious epidemiology, Pregnancy Complications, Infectious prevention & control
- Abstract
Background: In sub-Saharan Africa, administration of hepatitis B virus (HBV) birth-dose vaccines remains suboptimal. Evidence is scarce on whether African countries should focus on increasing vaccine coverage or developing strategies incorporating additional measures, such as peripartum antiviral prophylaxis to pregnant women at high risk. To better inform decision makers, we estimated the residual risk of mother-to-child transmission despite HBV birth-dose vaccine in Cameroon., Methods: We did a single-centre, longitudinal observational study. Pregnant women were systematically screened for HBV surface antigen (HBsAg) at Tokombéré District Hospital (Tokombéré district, Cameroon). Children born to HBsAg-positive mothers in 2009-16 who received the HBV birth-dose vaccine and three subsequent doses of pentavalent vaccine at 6, 10, and 14 weeks were followed up prospectively in 2015-17. In children, capillary blood was obtained for HBsAg rapid test and dried blood spots to quantify HBV DNA concentrations. Venous blood was also collected from HBsAg-positive children. Mother-to-child transmission was confirmed by whole-genome sequencing., Findings: Between Jan 31, 2009, and Dec 31, 2016, 22 243 (66·8%) of 33 309 pregnant women accepted antenatal HBV screening, of whom 3901 (17·5%) were HBsAg positive. 2004 (51·4%) of 3901 children who were born to HBsAg-positive mothers received the HBV birth-dose vaccine, of whom 1800 (89·8%) also completed the three-dose pentavalent vaccine. In total, the current analysis included 607 children who had a follow-up serosurvey. The prevalence of HBsAg was 5·6% in children who received the birth-dose vaccine in less than 24 h, 7·0% in those who received it 24-47 h after birth, and 16·7% in those who received it 48-96 h after birth (p
trend =0·083). 35 (89·7%) of 39 infected children were born to mothers positive for HBV e antigen with high HBV DNA of 5·3 log10 IU/mL or more. Whole-genome sequencing of HBV in infected mother-child pairs confirmed high identity proportions of 99·97-100%., Interpretation: We documented a substantial risk of mother-to-child transmission despite timely administration of the HBV birth-dose vaccine within 24 h after birth. To reach WHO's elimination targets, peripartum antiviral prophylaxis might be required in parts of Africa, in addition to increasing coverage of the HBV birth-dose vaccine., Funding: Agence nationale de recherches sur le sida et les hépatites virales (ANRS)., Competing Interests: Declaration of interests YS has received a research grant from Gilead. All other authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
24. A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.
- Author
-
Yuan Y, Zhang X, Chen R, Li Y, Wu B, Li R, Zou F, Ma X, Wang X, Chen Q, Deng J, Zhang Y, Chen T, Lin Y, Yan S, Zhang X, Li C, Bu X, Peng Y, Ke C, Deng K, Pan T, He X, Zhang Y, and Zhang H
- Subjects
- Animals, CHO Cells, COVID-19 Vaccines chemical synthesis, COVID-19 Vaccines immunology, COVID-19 Vaccines therapeutic use, Chlorocebus aethiops, Cricetulus, Female, HEK293 Cells, Humans, Macaca mulatta, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Nanoparticles, Vaccination methods, Vaccines, Combined chemical synthesis, Vaccines, Combined immunology, Vero Cells, COVID-19 prevention & control, Cross Protection immunology, SARS-CoV-2 immunology, Vaccines, Combined therapeutic use
- Abstract
Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
- Author
-
Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, Kumar P, Weber R, Levine E, Berger A, Bar A, Beck JT, Travers JB, Mihalcioiu C, Gastman B, Beitsch P, Rapisuwon S, Glaspy J, McCarron EC, Gupta V, Behl D, Blumenstein B, and Peterkin JJ
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cancer Vaccines pharmacology, Double-Blind Method, Female, Humans, Male, Middle Aged, Vaccines, Combined pharmacology, Young Adult, Cancer Vaccines therapeutic use, Melanoma drug therapy, Neoplasm Recurrence, Local drug therapy, Vaccines, Combined therapeutic use
- Abstract
Background: Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum. To assess the efficacy of seviprotimut-L, the Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) was initiated as a three-part multicenter, double-blind, placebo-controlled phase III trial. Results from part B1 are reported here., Methods: Patients with AJCC V.7 stage IIB-III cutaneous melanoma after resection were randomized 2:1, with stage stratification (IIB/C, IIIA, IIIB/C), to seviprotimut-L 40 mcg or placebo. Recurrence-free survival (RFS) was the primary endpoint. For an hypothesized HR of 0.625, one-sided alpha of 0.10, and power 80%, target enrollment was 325 patients., Results: For randomized patients (n=347), arms were well-balanced, and treatment-emergent adverse events were similar for seviprotimut-L and placebo. For the primary intent-to-treat endpoint of RFS, the estimated HR was 0.881 (95% CI: 0.629 to 1.233), with stratified logrank p=0.46. However, estimated HRs were not uniform over the stage randomized strata, with HRs (95% CIs) for stages IIB/IIC, IIIA, IIIB/IIIC of 0.67 (95% CI: 0.37 to 1.19), 0.72 (95% CI: 0.35 to 1.50), and 1.19 (95% CI: 0.72 to 1.97), respectively. In the stage IIB/IIC stratum, the effect on RFS was greatest for patients <60 years old (HR=0.324 (95% CI: 0.121 to 0.864)) and those with ulcerated primary melanomas (HR=0.493 (95% CI: 0.255 to 0.952))., Conclusions: Seviprotimut-L is very well tolerated. Exploratory efficacy model estimation supports further study in stage IIB/IIC patients, especially younger patients and those with ulcerated melanomas., Trial Registration Number: NCT01546571., Competing Interests: Competing interests: CLS discloses research funding to his University from Merck, Celldex, and GlaxoSmithKline; research support in kind to his University from Theraclion, 3M, Merck, and Celldex; Scientific Advisory Board role with Immatics (prior), and Curevac; principal investigator role for Polynoma with compensation to his university, related to this manuscript; and patent royalties as co-inventor of peptides for use in cancer vaccines (patents held by the UVA Licensing and Ventures Group). KDL received research funding from Polynoma. JH served on an advisory board for Nektar and BMS in 2020. SNM has received research grants from BMS and from Sorrento Pharma. TB is receiving time and effort support from Genentech for a melanoma prevention study and is the principal investigator for melanoma clinical studies sponsored by Genentech, Amgen, and Replimune. JC serves as consultant/speaker for Amgen, BMS, Merck, Novartis, Pfizer, Roche. SGH serves as an advisor to Incyte. BC has received honoraria from Merck (DSMB member), Clinigen (Ad board), Nektar (Ad Board), research support from Galectin Therapeutics, Clinigen. BMS (to Institution) and AstraZeneca (to Institution). MOB discloses roles on Advisory boards (Merck, BMS, Novartis, EMD Serono, Sanofi, Pfizer, Immunocore, GSK); safety Review Committees (GSK, Adaptimmune), and research funding from Merck and Takara Bio. JL has received research funding to his institution from BMS, Immunocore, Polynoma, Iovance and has participated in advisory boards from Regeneron and Array. DM directly is on speaker’s bureaus for Pfizer, Merck, Astellas, and SeaGen. TS serves on Advisory boards for Immunocore and Castle Biosciences. EH is on the speakers’ bureaus for Amgen and Castle Biosciences. SK is on the speakers’ bureau for Janssen, Pfizer, Roche/Genentech, AstraZeneca. RW is on a Speaker’s bureau for AstraZeneca. ABe has served as an advisor to Cardinal Health and Castle Biosciences. ABa is a consultant/speaker for Regeneron, Castle Biosciences, and receives research funding to her institution from Polynoma, Castle Biosciences, Pellepharm. CM has received grants, ad board and speaker fees from Novartis, BMS, Merck and Pfizer. VG is an investor in Medocity. DB: Research support- Natera; served on advisory boards for Merck, AstraZeneca, Novartis, Eli Lilly, Janssen, Oncocyte; speaker’s bureau-Janssen, Guardant. JJP is a paid consultant for Polynoma., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
26. Designing of Potential Polyvalent Vaccine Model for Respiratory Syncytial Virus by System Level Immunoinformatics Approaches.
- Author
-
Naqvi STQ, Yasmeen M, Ismail M, Muhammad SA, Nawazish-I-Husain S, Ali A, Munir F, and Zhang Q
- Subjects
- Alleles, Antigens, Codon, Computer Simulation, Epitopes, Epitopes, T-Lymphocyte, Glycoproteins chemistry, Histocompatibility Antigens Class I, Histocompatibility Antigens Class II, Hospitalization, Humans, Immune System, Molecular Docking Simulation, Proteasome Endopeptidase Complex, Protein Interaction Mapping, Proteomics, T-Lymphocytes immunology, Vaccines, Viral Fusion Proteins chemistry, Computational Biology methods, Respiratory Syncytial Virus Infections prevention & control, Respiratory Syncytial Virus, Human, Vaccines, Combined therapeutic use
- Abstract
Background: Respiratory syncytial virus (RSV) infection is a public health epidemic, leading to around 3 million hospitalization and about 66,000 deaths each year. It is a life-threatening condition exclusive to children with no effective treatment., Methods: In this study, we used system-level and vaccinomics approaches to design a polyvalent vaccine for RSV, which could stimulate the immune components of the host to manage this infection. Our framework involves data accession, antigenicity and subcellular localization analysis, T cell epitope prediction, proteasomal and conservancy evaluation, host-pathogen-protein interactions, pathway studies, and in silico binding affinity analysis., Results: We found glycoprotein (G), fusion protein (F), and small hydrophobic protein (SH) of RSV as potential vaccine candidates. Of these proteins (G, F, and SH), we found 9 epitopes for multiple alleles of MHC classes I and II bear significant binding affinity. These potential epitopes were linked to form a polyvalent construct using AAY, GPGPG linkers, and cholera toxin B adjuvant at N-terminal with a 23.9 kDa molecular weight of 224 amino acid residues. The final construct was a stable, immunogenic, and nonallergenic protein containing cleavage sites, TAP transport efficiency, posttranslation shifts, and CTL epitopes. The molecular docking indicated the optimum binding affinity of RSV polyvalent construct with MHC molecules (-12.49 and -10.48 kcal/mol for MHC classes I and II, respectively). This interaction showed that a polyvalent construct could manage and control this disease., Conclusion: Our vaccinomics and system-level investigation could be appropriate to trigger the host immune system to prevent RSV infection., Competing Interests: The authors state that there is no conflict of interest., (Copyright © 2021 Syeda Tahira Qousain Naqvi et al.)
- Published
- 2021
- Full Text
- View/download PDF
27. Field evaluation of a sing-dose bivalent vaccine of porcine circovirus type 2b and Mycoplasma hyopneumoniae.
- Author
-
Yang S, Ahn Y, Oh T, Cho H, Park KH, and Chae C
- Subjects
- Animals, Circoviridae Infections therapy, Circoviridae Infections virology, Circovirus immunology, Mycoplasma hyopneumoniae immunology, Pneumonia of Swine, Mycoplasmal microbiology, Sus scrofa, Swine, Swine Diseases therapy, Bacterial Vaccines therapeutic use, Circoviridae Infections veterinary, Pneumonia of Swine, Mycoplasmal therapy, Vaccines, Combined therapeutic use, Viral Vaccines therapeutic use
- Abstract
Background: The field efficacy of a bivalent vaccine containing porcine circovirus type 2b (PCV2b) and Mycoplasma hyopneumoniae was evaluated on three pig farms., Methods: Three pig farms were used, two of which had a history of subclinical PCV2 and clinical M. hyopneumoniae infections between 84 and 126 days of age while concurrent porcine circovirus-associated disease and clinical M. hyopneumoniae infection between 70 and 105 days of age. Each farm vaccinated pigs with a single dose of a bivalent vaccine at 10 days of age while unvaccinated pigs were administered a single dose of phosphate buffered-saline at the same age., Results: Vaccination improved growth performance and reduced clinical scores significantly (p < .05) when compared with unvaccinated animals. The amount of PCV2d loads in blood and M. hyopneumoniae loads in nasal swabs of vaccinated animals were also significantly lower (p < .05) when compared with unvaccinated animals. Immunologically, vaccinated groups elicited a significantly higher (p < .05) level of protective immunity against PCV2d such as neutralizing antibodies and interferon-γ secreting cells (IFN-γ-SC), as well as protective immunity against M. hyopneumoniae such as IFN-γ-SC when compared with unvaccinated animals. Pathologically, vaccination significantly lowered (p < .05) the scores of M. hyopneumoniae-induced pneumonia and PCV2-associated lymphoid lesions when compared with unvaccinated animals., Conclusions: The evaluated bivalent vaccine provided good protection against PCV2d and M. hyopneumoniae infection under field conditions., (© 2020 The Authors Veterinary Medicine and Science Published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
28. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Author
-
Bilusic M, McMahon S, Madan RA, Karzai F, Tsai YT, Donahue RN, Palena C, Jochems C, Marté JL, Floudas C, Strauss J, Redman J, Abdul Sater H, Rabizadeh S, Soon-Shiong P, Schlom J, and Gulley JL
- Subjects
- Adenoviridae genetics, Aged, Aged, 80 and over, Cancer Vaccines adverse effects, Cancer Vaccines genetics, Cancer Vaccines immunology, Fetal Proteins genetics, Genetic Vectors, Humans, Kallikreins genetics, Male, Middle Aged, Mucin-1 genetics, Progression-Free Survival, Prostate-Specific Antigen genetics, Prostatic Neoplasms, Castration-Resistant genetics, Prostatic Neoplasms, Castration-Resistant immunology, T-Box Domain Proteins genetics, Time Factors, Vaccination, Vaccine Efficacy, Vaccines, Combined adverse effects, Vaccines, Combined genetics, Vaccines, Combined immunology, Viral Vaccines, Adenoviridae immunology, Cancer Vaccines therapeutic use, Fetal Proteins immunology, Kallikreins immunology, Mucin-1 immunology, Prostate-Specific Antigen immunology, Prostatic Neoplasms, Castration-Resistant therapy, T-Box Domain Proteins immunology, Vaccines, Combined therapeutic use
- Abstract
Background: Antitumor vaccines targeting tumor-associated antigens (TAAs) can generate antitumor immune response. A novel vaccine platform using adenovirus 5 (Ad5) vectors [E1-, E2b-] targeting three TAAs-prostate-specific antigen (PSA), brachyury, and MUC-1-has been developed. Both brachyury and the C-terminus of MUC-1 are overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and have been shown to play an important role in resistance to chemotherapy, epithelial-mesenchymal transition, and metastasis. The transgenes for PSA, brachyury, and MUC-1 all contain epitope modifications for the expression of CD8+ T-cell enhancer agonist epitopes. We report here the first-in-human trial of this vaccine platform., Methods: Patients with mCRPC were given concurrently three vaccines targeting PSA, brachyury, and MUC-1 at 5×10
11 viral particles (VP) each, subcutaneously every 3 weeks for a maximum of three doses (dose de-escalation cohort), followed by a booster vaccine every 8 weeks for 1 year (dose-expansion cohort only). The primary objective was to determine the safety and the recommended phase II dose. Immune assays and clinical responses were evaluated., Results: Eighteen patients with mCRPC were enrolled between July 2018 and September 2019 and received at least one vaccination. Median PSA was 25.58 ng/mL (range, 0.65-1006 ng/mL). The vaccine was tolerable and safe, and no grade >3 treatment-related adverse events or dose-limiting toxicities (DLTs) were observed. One patient had a partial response, while five patients had confirmed PSA decline and five had stable disease for >6 months. Median progression-free survival was 22 weeks (95% CI: 19.1 to 34). Seventeen (100%) of 17 patients mounted T-cell responses to at least one TAA, whereras 8 (47%) of 17 patients mounted immune responses to all three TAAs. Multifunctional T-cell responses to PSA, MUC-1, and brachyury were also detected after vaccination in the majority of the patients., Conclusions: Ad5 PSA/MUC-1/brachyury vaccine is well tolerated. The primary end points were met and there were no DLTs. The recommended phase II dose is 5×1011 VP. The vaccine demonstrated clinical activity, including one partial response and confirmed PSA responses in five patients. Three patients with prolonged PSA responses received palliative radiation therapy. Further research is needed to evaluate the clinical benefit and immunogenicity of this vaccine in combination with other immuno-oncology agents and/or palliative radiation therapy., Trial Registration Number: NCT03481816., Competing Interests: Competing interests: ImmunityBio authors are employees of ImmunityBio, Inc., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2021
- Full Text
- View/download PDF
29. Knowledge among the rural parents about the vaccinations and vaccination coverage of children in the first year of life in Papua New Guinea - analysis of data provided by Christian health services.
- Author
-
Gowin E, Kuzma J, and Januszkiewicz-Lewandowska D
- Subjects
- Adult, Community Networks, Female, Humans, Immunization psychology, Immunization statistics & numerical data, Immunization Programs statistics & numerical data, Infant, Infant, Newborn, Male, Measles Vaccine therapeutic use, Papua New Guinea epidemiology, Surveys and Questionnaires, Vaccines, Combined therapeutic use, Knowledge, Parents education, Parents psychology, Rural Population statistics & numerical data, Vaccination psychology, Vaccination statistics & numerical data, Vaccination Coverage statistics & numerical data
- Abstract
Knowledge among the rural parents about the vaccinations and vaccination coverage of children in the first year of life in Papua New Guinea - analysis of data provided by Christian Health Services., Background: This analysis aimed to assess rural parents' knowledge about the diseases prevented by vaccinations and establish vaccination coverage in PNG., Methods: Knowledge of vaccinations was checked through a standard questionnaire (five closed questions). We analyzed data on vaccination coverage from 2016 to 2018 from all Catholic health facilities. Analyzed vaccinations were the pentavalent vaccine (DTaP-HiB-HepB) and measles vaccine given in the first year of life. Coverage was calculated based on the number of vaccines used compared to the number of eligible children. Analyzed vaccinations were the pentavalent vaccine (DTaP-HiB-HepB) and measles vaccine given in the first year of life., Results: Fifty-six parents, including 52 mothers and four fathers, participated in the interview. Many parents (46%) understood that the vaccine prevents diseases. During the analyzed period, 25,502 doses of measles vaccine were given, 31,428 children were vaccinated with the pentavalent vaccine. In 2016, the measles vaccine coverage rate was 26.6 and 33.4% for the pentavalent vaccine. In 2017, measles and pentavalent vaccines' coverage rate was 12.5 and 16.6%, respectively. There were significant differences in immunization coverage between provinces. A decreasing trend in the number of administered vaccinations was observed., Conclusion: The results of this analysis demonstrate that in PNG, the majority of children are not fully immunized. There are significant differences in the vaccination coverage between provinces. As protection from diseases is low, there is a very high risk of an outbreak of the vaccine-preventable disease in the community. Delivery of vaccinations in PNG encounters many barriers, from access to healthcare services to natural disasters and inter-tribial conflicts.
- Published
- 2021
- Full Text
- View/download PDF
30. Acceptance of universal varicella vaccination among Swiss pediatricians and general practitioners who treat pediatric patients.
- Author
-
Lienert F, Weiss O, Schmitt K, Heininger U, and Guggisberg P
- Subjects
- Chickenpox epidemiology, Chickenpox virology, Chickenpox Vaccine immunology, Female, Humans, Immunization Programs, Incidence, Male, Parents psychology, Surveys and Questionnaires, Switzerland epidemiology, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, Chickenpox prevention & control, Chickenpox Vaccine therapeutic use, General Practitioners psychology, Health Knowledge, Attitudes, Practice, Herpesvirus 3, Human immunology, Pediatricians psychology, Vaccination psychology
- Abstract
Background: Over the last two decades, several countries have initiated universal varicella vaccination (UVV) programs in infants. In 2019, the Swiss National Immunization Technical Advisory Group (NITAG) decided to start evaluating the introduction of universal varicella vaccination. There is a theoretical concern that suboptimal vaccination coverage could lead to a shift in the varicella incidence to older age groups, thereby potentially increasing complication rates. To achieve a high vaccination coverage rate, it is important that practicing physicians comply with a potential recommendation for UVV. We studied the perception of varicella and the current vaccination behavior among Swiss pediatricians and general practitioners (GPs) who treat children. We also assessed their intention to advise parents to vaccinate their children against varicella in the event the Swiss NITAG will recommend UVV., Methods: Primary data was collected through a structured, 20-min online survey with Swiss pediatricians and GPs who treat children., Results: 150 physicians participated in the study: 40 GPs in the German-speaking part, 20 GPs in the French-speaking part, 67 pediatricians in the German-speaking part, and 23 pediatricians in the French-speaking part. The majority (64%) of all participants reported that they currently recommend varicella vaccination for risk groups according to the national immunization plan. About one third of physicians (35%) - predominantly pediatricians - currently already recommend it for all infants. In these situations, a measles, mumps, rubella, varicella combination vaccine is currently used by 58% for the first dose and by 59% for the second dose. 86% of participants stated that they would advise parents to have their children vaccinated against varicella in case of a recommendation for UVV by the Swiss NITAG. 68% responded that they expect many questions from parents and 65% agreed that they have good arguments to convey the importance of varicella vaccination., Conclusions: The survey study results show that most participating pediatricians and GPs indicated a favorable attitude towards childhood vaccination against varicella in the setting of a Swiss NITAG recommendation for UVV. This data shows the importance of NITAG recommendations in influencing vaccine education and supporting achievement of high coverage of varicella vaccination.
- Published
- 2021
- Full Text
- View/download PDF
31. Polyvalent therapeutic vaccine for type 2 diabetes mellitus: Immunoinformatics approach to study co-stimulation of cytokines and GLUT1 receptors.
- Author
-
Muhammad SA, Ashfaq H, Zafar S, Munir F, Jamshed MB, Chen J, and Zhang Q
- Subjects
- Amino Acid Sequence, Antigens immunology, Conserved Sequence, Diabetes Mellitus, Type 2 genetics, Epitopes, T-Lymphocyte chemistry, Epitopes, T-Lymphocyte immunology, Glucose metabolism, Histocompatibility Antigens Class I immunology, Humans, Lymphocyte Activation immunology, Molecular Docking Simulation, Molecular Sequence Annotation, Proteasome Endopeptidase Complex metabolism, Protein Interaction Maps, Cytokines metabolism, Diabetes Mellitus, Type 2 immunology, Diabetes Mellitus, Type 2 therapy, Glucose Transporter Type 1 metabolism, Vaccines, Combined therapeutic use
- Abstract
Background: Type 2 diabetes mellitus (T2DM) is a worldwide disease that have an impact on individuals of all ages causing micro and macro vascular impairments due to hyperglycemic internal environment. For ultimate treatment to cure T2DM, association of diabetes with immune components provides a strong basis for immunotherapies and vaccines developments that could stimulate the immune cells to minimize the insulin resistance and initiate gluconeogenesis through an insulin independent route., Methodology: Immunoinformatics based approach was used to design a polyvalent vaccine for T2DM that involved data accession, antigenicity analysis, T-cell epitopes prediction, conservation and proteasomal evaluation, functional annotation, interactomic and in silico binding affinity analysis., Results: We found the binding affinity of antigenic peptides with major histocompatibility complex (MHC) Class-I molecules for immune activation to control T2DM. We found 13-epitopes of 9 amino acid residues for multiple alleles of MHC class-I bears significant binding affinity. The downstream signaling resulted by T-cell activation is directly regulated by the molecular weight, amino acid properties and affinity of these epitopes. Each epitope has important percentile rank with significant ANN IC
50 values. These high score potential epitopes were linked using AAY, EAAAK linkers and HBHA adjuvant to generate T-cell polyvalent vaccine with a molecular weight of 35.6 kDa containing 322 amino acids residues. In silico analysis of polyvalent construct showed the significant binding affinity (- 15.34 Kcal/mol) with MHC Class-I. This interaction would help to understand our hypothesis, potential activation of T-cells and stimulatory factor of cytokines and GLUT1 receptors., Conclusion: Our system-level immunoinformatics approach is suitable for designing potential polyvalent therapeutic vaccine candidates for T2DM by reducing hyperglycemia and enhancing metabolic activities through the immune system.- Published
- 2020
- Full Text
- View/download PDF
32. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
- Author
-
Garbuglia AR, Lapa D, Sias C, Capobianchi MR, and Del Porto P
- Subjects
- Adolescent, Adult, Capsid Proteins immunology, Child, Female, Humans, Immunogenicity, Vaccine, Middle Aged, Papillomavirus E7 Proteins immunology, Papillomavirus Infections virology, Papillomavirus Vaccines immunology, Treatment Outcome, Vaccines, Combined immunology, Young Adult, Alphapapillomavirus immunology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines therapeutic use, Pre-Exposure Prophylaxis methods, Vaccination methods, Vaccines, Combined therapeutic use
- Abstract
Human papillomavirus (HPV) is the most common sexually transmitted virus. The high-risk HPV types (i.e., HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the main etiological agents of genital tract cancers, such as cervical, vulvar, vaginal, penile, and anal cancers, and of a subset of head and neck cancers. Three prophylactic HPV vaccines are available that are bivalent (vs. HPV16, 18), tetravalent (vs. HPV6, 11, 16, 18), and non-avalent (vs. HPV6, 11, 16, 18, 31, 33,45, 52, 58). All of these vaccines are based on recombinant DNA technology, and they are prepared from the purified L1 protein that self-assembles to form the HPV type-specific empty shells (i.e., virus-like particles). These vaccines are highly immunogenic and induce specific antibodies. Therapeutic vaccines differ from prophylactic vaccines, as they are designed to generate cell-mediated immunity against transformed cells, rather than neutralizing antibodies. Among the HPV proteins, the E6 and E7 oncoproteins are considered almost ideal as targets for immunotherapy of cervical cancer, as they are essential for the onset and evolution of malignancy and are constitutively expressed in both premalignant and invasive lesions. Several strategies have been investigated for HPV therapeutic vaccines designed to enhance CD4
+ and CD8+ T-cell responses, including genetic vaccines (i.e., DNA/ RNA/virus/ bacterial), and protein-based, peptide-based or dendritic-cell-based vaccines. However, no vaccine has yet been licensed for therapeutic use. Several studies have suggested that administration of prophylactic vaccines immediately after surgical treatment of CIN2 cervical lesions can be considered as an adjuvant to prevent reactivation or reinfection, and other studies have described the relevance of prophylactic vaccines in the management of genital warts. This review summarizes the leading features of therapeutic vaccines, which mainly target the early oncoproteins E6 and E7, and prophylactic vaccines, which are based on the L1 capsid protein. Through an analysis of the specific immunogenic properties of these two types of vaccines, we discuss why and how prophylactic vaccines can be effective in the treatment of HPV-related lesions and relapse., (Copyright © 2020 Garbuglia, Lapa, Sias, Capobianchi and Del Porto.)- Published
- 2020
- Full Text
- View/download PDF
33. [Continue to use the bivalent HPV vaccine; bivalent vaccine more effective than expected].
- Author
-
Postma MJ and Wilschut JC
- Subjects
- Condylomata Acuminata, Female, Humans, Immunization Programs, Netherlands, Papillomavirus Infections virology, Papillomavirus Vaccines immunology, Uterine Cervical Neoplasms virology, Vaccines, Combined immunology, Uterine Cervical Dysplasia virology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines therapeutic use, Uterine Cervical Neoplasms prevention & control, Vaccines, Combined therapeutic use, Uterine Cervical Dysplasia prevention & control
- Abstract
It is becoming clear that there are significant differences between the two principal human papillomavirus (HPV) vaccines, namely the bivalent vaccine and the quadrivalent vaccine. Both vaccines contain HPV16 and HPV18, together responsible for approximately 73% of cases of cervical cancer. The quadrivalent vaccine also contains HPV6 and HPV11, thus protecting against genital warts. Real-world data show 89% efficacy for the bivalent vaccine against cervical intraepithelial neoplasia stage 3, irrespective of the HPV type involved, versus 64% for the quadrivalent vaccine. This suggests superior cross-reactivity of the bivalent vaccine against oncogenic HPV types not contained in the vaccine, presumably thanks to the MPLA adjuvant in the vaccine. In the Netherlands, the cross-reactivity of the bivalent vaccine may ultimately lead to a significant additional reduction of cervical cancer deaths per year. Since protection against genital warts should not be pursued at the expense of protection against cervical cancer, we recommend that the Netherlands continue to use the bivalent vaccine in its national immunisation programme.
- Published
- 2020
34. [HPV vaccination with quadrivalent or nonavalent vaccine: an opportunity to eliminate genital warts as well].
- Author
-
van Bergen JEAM
- Subjects
- Adult, Condylomata Acuminata virology, Female, Humans, Immunization Programs, Netherlands, Papillomavirus Infections virology, Papillomavirus Vaccines immunology, Sexual Behavior, Uterine Cervical Neoplasms prevention & control, Uterine Cervical Neoplasms virology, Vaccines, Combined immunology, Condylomata Acuminata prevention & control, Papillomavirus Infections prevention & control, Papillomavirus Vaccines therapeutic use, Vaccines, Combined therapeutic use
- Abstract
The impact of genital warts on psychological, social and sexual wellbeing is often overlooked, as is the magnitude of the problem. In 2017, the number of consultations in primary care in the Netherlands was 42,000. Real-world evidence shows compelling and impressive results regarding the reduction of genital warts in other countries. Not opting for a vaccine that also protects against genital warts is a missed opportunity for elimination of cervical cancer as well as genital warts.
- Published
- 2020
35. Vaccination Status and Associated Factors among Street Children 9-24 Months Old in Sidama Region, Ethiopia.
- Author
-
Deressa AT, Desta MS, and Belihu TM
- Subjects
- Adolescent, Adult, Birth Setting statistics & numerical data, Child, Preschool, Ethiopia, Female, Health Knowledge, Attitudes, Practice, Humans, Infant, Logistic Models, Male, Multivariate Analysis, Odds Ratio, Prenatal Care statistics & numerical data, Risk Factors, Vaccination Coverage statistics & numerical data, Young Adult, Home Childbirth statistics & numerical data, Homeless Youth statistics & numerical data, Maternal Age, Vaccination statistics & numerical data, Vaccines, Combined therapeutic use
- Abstract
Background: Childhood non-vaccination can have different short-and long-term negative outcomes on their health. In Ethiopia, in addition to low coverage of full vaccination, street children were among the neglected part of the community who were missed during planning and reporting vaccination coverage. Moreover, there is no related research conducted on this title specifically., Objective: The objective of the study was to assess the vaccination status and its associated factors among street children 9-24 months old in Sidama zone., Methods: Community-based cross-sectional study design was conducted in four selected towns of Sidama region, southern Ethiopia. The convenience sampling method was applied to involve mothers of street children younger than two years during the study period. Data entry was done with EpiData version 3.1 and exported to SPSS22 for analysis. Bivariate and multivariable logistic regression analysis were performed to identify factors associated with immunization status of street children., Results: A significant number (26 [24.3%]) of the street children younger than two years were not vaccinated. Those mothers who are ≤20 years old (P = 0.014, AOR = 0.216, 95% CI: 0.064-0.732) and who gave birth at home (P = 0.029, AOR = 0.292, 95% CI: 0.097-0.879) had less odds of vaccinating their child than those older than 20 and who gave birth at health facility respectively., Conclusion: A significant number of the street children in this study are not fully vaccinated. Mothers aged <20 years and home births were significantly associated with non-vaccination status., Competing Interests: The authors have no competing interests to declare., (Copyright: © 2020 The Author(s).)
- Published
- 2020
- Full Text
- View/download PDF
36. Combined vaccines for prophylaxis of infectious conditions.
- Author
-
Shende P and Waghchaure M
- Subjects
- Bacterial Vaccines immunology, Bacterial Vaccines therapeutic use, Humans, Adjuvants, Immunologic therapeutic use, Meningococcal Infections immunology, Meningococcal Infections prevention & control, Pneumonia immunology, Pneumonia prevention & control, Respiratory Syncytial Virus Infections immunology, Respiratory Syncytial Virus Infections prevention & control, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, Viral Vaccines immunology, Viral Vaccines therapeutic use
- Abstract
In recent years, the application of vaccines shows limitations, including the high number of vaccine administrations and the fear of safety and effectiveness. In this regard, advanced vaccine products have been developed, like the combined vaccines, or are under development, such as nucleic acid vaccines (DNA and RNA), polymer-based vaccines, etc. Moreover, the possible use of traditional, like aluminium hydroxide and aluminium phosphate, or innovative adjuvants, like monophosphoryl lipid A, polysaccharides and nanoparticulate system, may further increase vaccine effectiveness. This review article focuses on the combined vaccines, which, especially when they are associated with adjuvants, reduce the dosing frequency, and prolong the duration of action, thus providing better vaccine coverage. Marketed preparations, like Typhim Vi, Peda typh and Boostrix showed better vaccine coverage for diseases like typhoid, tetanus, diphtheria and acellular pertussis. The future aspect for the development of combined vaccines will protect not only against infectious diseases but likely even against various infectious conditions, like pneumonia, meningococcal infection and respiratory syncytial virus infection.
- Published
- 2019
- Full Text
- View/download PDF
37. Design and immunogenicity analysis of the combined vaccine against zoonotic hepatitis E and foot-and-mouth disease.
- Author
-
Liu Z, Behloul N, Baha S, Wei W, Shi R, and Meng J
- Subjects
- Animals, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Antigens, Viral immunology, Female, Foot-and-Mouth Disease immunology, Foot-and-Mouth Disease Virus immunology, Hepatitis E immunology, Hepatitis E virology, Mice, Mice, Inbred BALB C, Neutralization Tests, Vaccination methods, Foot-and-Mouth Disease pathology, Foot-and-Mouth Disease virology, Foot-and-Mouth Disease Virus pathogenicity, Hepatitis E prevention & control, Vaccines, Combined therapeutic use, Viral Hepatitis Vaccines therapeutic use
- Abstract
Aim: Design and immunogenicity assessment of the combined vaccine candidate against zoonotic hepatitis E virus (HEV) and foot-and-mouth disease virus (FMDV)., Methods: Using the molecular cloning technology, we produced and purified 9 HEV ORF2-truncated proteins (HEV genotype 4). Then, we compared their thermal stability, antigenicity, and immunogenicity to select the best HEV immunogen. Next, we used the adjuvant Montanide ISA-206 to prepare different formulations of HEV vaccine alone, FMDV vaccine alone and HEV-FMDV combined vaccine. The formulations were injected into mice and the induced humoral immune responses were monitored up 12 weeks post-immunization., Results: The HEV p222 protein could self-assemble into VLPs (∼34 nm) and showed higher stability and better antigenicity/immunogenicity than the other HEV antigens, thus it was selected as the best HEV immunogen. Mice immunization with the FMDV vaccine alone induced high FMDV-specific antibody titers in a dose-dependent manner; the HEV p222 protein also induced high levels of anti-HEV antibodies but in a dose-independent manner. The HEV-FMDV combination induced anti-FMDV antibody titers 7-16-fold higher than the titers induced by the FMDV vaccine alone, and HEV-specific antibody titers 2.4-fold higher than those induced by the HEV p222 antigen alone., Conclusion: Herein, we proposed a new approach for the control of zoonotic HEV infection through its control in its main host (pig). We also designed the first HEV-FMDV combined vaccine and the preliminary analyses revealed a synergistic effect on the immunogenicity of both HEV and FMDV antigens., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
38. DTaP-IPV-HepB-Hib Vaccine (Hexyon ® ): An Updated Review of its Use in Primary and Booster Vaccination.
- Author
-
Syed YY
- Subjects
- Diphtheria-Tetanus-Pertussis Vaccine pharmacology, Female, Haemophilus Vaccines pharmacology, Hepatitis B Vaccines pharmacology, Humans, Male, Poliovirus Vaccine, Inactivated pharmacology, Vaccines, Combined pharmacology, Vaccines, Combined therapeutic use, Diphtheria-Tetanus-Pertussis Vaccine therapeutic use, Haemophilus Vaccines therapeutic use, Hepatitis B Vaccines therapeutic use, Poliovirus Vaccine, Inactivated therapeutic use, Vaccination methods
- Abstract
Hexyon
® is a fully-liquid, ready-to-use, hexavalent vaccine approved in the EU since 2013 for primary and booster vaccination in infants and toddlers from age 6 weeks against diphtheria, tetanus, pertussis, hepatitis B (HB), poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). While the source of HB antigen in Hexyon® is different from other vaccines, the rest of its valences have been extensively used in other approved vaccines. Hexyon® is highly immunogenic for all its component toxoids/antigens when used as primary and booster vaccine in infants and toddlers, irrespective of vaccination schedule. It provides durable protection against hepatitis B. Hexyon® can be used for a mixed primary series of hexavalent-pentavalent-hexavalent vaccines or as a booster in infants primed with Infanrix hexa™ or pentavalent (whole-cell or acellular pertussis) vaccines. Coadministration of Hexyon® with other common childhood vaccines did not affect immune response to any vaccines. Hexyon® has a good reactogenicity/safety profile. The immunogenicity and safety profile of Hexyon® was similar to that of several approved vaccines, including Infanrix hexa™. However, Hexyon® offers the convenience of full-liquid, ready-to-use formulation, which may minimize vaccination errors and preparation time. Thus, Hexyon® is a convenient, useful option for vaccination against childhood diseases caused by six major pathogens.- Published
- 2019
- Full Text
- View/download PDF
39. Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study.
- Author
-
Susarla SK, Gupta M, Mantan M, Dhongade R, Bhave S, Das RK, Ray RK, Ramesh Babu T, Ravi MD, Krishnamurthy B, James S, Sandhya G, Satish M, and Sahoo DP
- Subjects
- Antibody Formation immunology, Antibody Formation physiology, Female, Haemophilus influenzae type b immunology, Haemophilus influenzae type b pathogenicity, Hepatitis B virus immunology, Hepatitis B virus pathogenicity, Humans, India, Infant, Male, Single-Blind Method, Diphtheria-Tetanus-Pertussis Vaccine therapeutic use, Haemophilus Vaccines therapeutic use, Poliovirus Vaccine, Inactivated therapeutic use, Vaccination methods, Vaccines, Combined therapeutic use
- Abstract
Background: A liquid Pentavalent (DTwP-Hb-Hib) combination vaccine, developed by Human Biologicals Institute, underwent a Phase III clinical study in India. In this randomized, single blind, non-inferiority study, the immunogenicity and safety of this Investigational vaccine was compared with Pentavac SD® vaccine in 6-8 weeks old healthy infants., Methods: A total of 405 healthy infants aged 6-8 weeks old were randomized in 2:1 ratio to receive three doses of either the Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine or Pentavac SD® vaccine at four to six weeks interval. Immunogenicity was compared by estimation of antibody titers before the first dose and 4-6 weeks after the third dose of vaccination. Safety of each vaccine was assessed and compared by collection of data on solicited and unsolicited adverse events throughout the study period., Results: Out of a total of 405 enrolled subjects, 387 subjects completed the study. The seroconversion rates, seroprotection rates and geometric mean titres of the Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine group were found to be comparable and non-inferior to the Pentavac SD® vaccine group at 4-6 weeks after the third dose of vaccination. Pain, erythema and swelling at the site of injection were found to be the most common local adverse events whereas fever, irritability and unusual crying were found to be the most common systemic adverse events in both the vaccine groups. No vaccine related serious adverse event was reported. In this study, both the Investigational vaccine as well as the Comparator vaccine were found to be immunogenic and well tolerated., Conclusion: After assessment of the results of the study it was concluded that the Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine developed by Human Biologicals Institute was immunogenic and safe when administered to infants aged 6-8 weeks and was non-inferior in immunogenicity and safety to Pentavac SD® vaccine. Clinical Trial Registry of India Identifier: CTRI/2016/01/006541., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
40. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
- Author
-
Carryn S, Feyssaguet M, Povey M, and Di Paolo E
- Subjects
- Antibodies, Viral immunology, Chickenpox Vaccine therapeutic use, Child, Preschool, Female, Follow-Up Studies, Humans, Infant, Male, Measles immunology, Measles prevention & control, Measles-Mumps-Rubella Vaccine immunology, Mumps immunology, Mumps prevention & control, Mumps virus immunology, Mumps virus pathogenicity, Rubella immunology, Rubella prevention & control, Rubella virus immunology, Rubella virus pathogenicity, Vaccination, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, Measles-Mumps-Rubella Vaccine therapeutic use
- Abstract
Measles and mumps outbreaks still occur in countries that have successfully implemented universal routine immunization programs. Measles outbreaks are mostly associated to absent or incomplete vaccination, whereas for mumps outbreaks the combined effects of waning of immunity and circulating new strains are incriminated. It is therefore increasingly useful to characterize the long-lasting immunity induced by measles-, mumps, and rubella (MMR)-containing vaccines. In this 10-year study, 1887 healthy children aged 12-22 months, randomized to receive 1 or 2 doses of MMR-containing vaccines (Priorix or Priorix-Tetra; GSK), were included in an antibody persistence analysis. A total of 364 children in the 1-dose group received a second dose out of study according to their local vaccination schedule between Years 4 and 10 post-dose 1, and were included in a separate post-hoc analysis to evaluate the effect of the second dose when given later. Anti-measles, -mumps and -rubella antibody titers were measured by commercial ELISA kits (Enzygnost, Siemens) after each vaccine dose and at Years 1, 2, 4, 6, 8 and 10 post-vaccination. Antibodies against measles and rubella declined moderately after vaccination but remained well above the seropositivity threshold after 10 years. The anti-measles antibody titers elicited by Priorix-Tetra remained about 2-fold higher throughout the study as compared with Priorix. A second dose of MMR vaccine later in life had a minor and transient effect on anti-measles and anti-rubella waning titers. In contrast, anti-mumps antibody levels remained relatively stable over the 10-year follow-up and a second dose of MMR vaccine, given anytime over the 10-year period, had a boosting effect on anti-mumps antibody titers and seropositivity rates. In conclusion, 1 or 2 doses of MMR-containing vaccines given to children in their second year of life induced antibody responses against measles, mumps and rubella viruses that persisted at least up to 10 years post-vaccination. Clinical trial registration number: NCT00226499., (Copyright © 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
41. Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma.
- Author
-
Zhang Q, Xie C, Wang D, Yang Y, Liu H, Liu K, Zhao J, Chen X, Zhang X, Yang W, Li X, Tian F, Dong Z, and Lu J
- Subjects
- Animals, Cell Line, Tumor, Dendritic Cells immunology, Female, Human Umbilical Vein Endothelial Cells, Humans, Immunotherapy, Mice, Mice, Inbred BALB C, Cancer Vaccines therapeutic use, Colorectal Neoplasms therapy, Tumor Microenvironment immunology, Vaccines, Combined therapeutic use
- Abstract
Angiogenesis is essential for the development, growth, and metastasis of solid tumors. Vaccination with viable human umbilical vein endothelial cells (HUVECs) has been used for antitumor angiogenesis. However, the limited immune response induced by HUVECs hinders their clinical application. In the present study, we found that HUVECs induced by a tumor microenvironment using the supernatant of murine CT26 colorectal cancer cells exerted a better antiangiogenic effect than HUVECs themselves. The inhibitory effect on tumor growth in the induced HUVEC group was significantly better than that of the HUVEC group, and the induced HUVEC group showed a strong inhibition in CD31-positive microvessel density in the tumor tissues. Moreover, the level of anti-induced HUVEC membrane protein antibody in mouse serum was profoundly higher in the induced HUVEC group than in the HUVEC group. Based on this, the antitumor effect of a vaccine with a combination of induced HUVECs and dendritic cell-loading CT26 antigen (DC-CT26) was evaluated. Notably, the microvessel density of tumor specimens was significantly lower in the combined vaccine group than in the control groups. Furthermore, the spleen index, the killing effect of cytotoxic T lymphocytes (CTLs), and the concentration of interferon-γ in the serum were enhanced in the combined vaccine group. Based on these results, the combined vaccine targeting both tumor angiogenesis and tumor cells may be an attractive and effective cancer immunotherapy strategy., Competing Interests: The authors declare no conflict of interest.
- Published
- 2019
- Full Text
- View/download PDF
42. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
- Author
-
Barug D, Pronk I, van Houten MA, Versteegh FGA, Knol MJ, van de Kassteele J, Berbers GAM, Sanders EAM, and Rots NY
- Subjects
- Adolescent, Adult, Antibodies, Bacterial blood, Antibody Formation, Antigens, Bacterial immunology, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Female, Humans, Immunization, Secondary, Immunoglobulin G blood, Infant, Infant, Newborn, Male, Netherlands, Pertussis Toxin immunology, Pregnancy, Treatment Outcome, Vaccines, Combined immunology, Vaccines, Combined therapeutic use, Whooping Cough microbiology, Young Adult, Bordetella pertussis immunology, Diphtheria-Tetanus-Pertussis Vaccine immunology, Diphtheria-Tetanus-Pertussis Vaccine therapeutic use, Diphtheria-Tetanus-acellular Pertussis Vaccines immunology, Diphtheria-Tetanus-acellular Pertussis Vaccines therapeutic use, Haemophilus Vaccines immunology, Haemophilus Vaccines therapeutic use, Hepatitis B Vaccines immunology, Hepatitis B Vaccines therapeutic use, Pneumococcal Vaccines therapeutic use, Poliovirus Vaccine, Inactivated immunology, Poliovirus Vaccine, Inactivated therapeutic use, Vaccination methods, Whooping Cough prevention & control
- Abstract
Background: Maternal tetanus, diphtheria, and acellular pertussis (Tdap) vaccination offers protection for neonates against clinical pertussis until primary vaccinations, but maternal antibodies also interfere with infants' immune responses to primary vaccinations. We investigated the effect of maternal Tdap vaccination on the pertussis antibody responses of infants starting primary vaccinations at age 3 months., Methods: In an open-label, parallel, randomised, controlled trial, pregnant women aged 18-40 years with a low risk of pregnancy complications were recruited through independent midwives at 36 midwife clinics in the Netherlands and received Tdap vaccination either at 30-32 weeks of pregnancy (maternal Tdap group) or within 48 h after delivery (control group). All term-born infants were vaccinated with the diphtheria, tetanus, and pertussis-inactivated poliomyelitis-Haemophilus influenzae type B-hepatitis B six-in-one vaccine and a ten-valent pneumococcal vaccine at 3 months, 5 months, and 11 months. Randomisation was done using a number generator in a 1:1 ratio and with sealed envelopes. Participants and clinical trial staff were not masked, but laboratory technicians were unaware of study group assignments. The primary endpoint was serum IgG pertussis toxin antibody concentrations at age 3 months. Cord blood and infant blood samples were collected at age 2 months, 3 months, 6 months, 11 months, and 12 months. Analysis was done by modified intention to treat with all randomly assigned participants in case a laboratory result was available. This trial is registered with ClinicaltTrialsRegister.eu (EudraCT 2012-004006-9) and trialregister.nl (NTR number NTR4314). The trial is now closed to new participants., Findings: Between Jan 16, 2014, and March 4, 2016, 118 pregnant women were enrolled into our study, with 58 in the maternal Tdap group and 60 in the control group. The geometric mean concentration (GMC) of pertussis toxin antibodies were higher in infants in the maternal Tdap group than in the control group infants at age 3 months (GMC ratio 16·6, 95% CI 10·9-25·2) and also significantly higher compared with control infants at age 2 months. After primary vaccinations, antibody concentrations for pertussis toxin, filamentous haemagglutinin, and pertactin were significantly lower at all timepoints in infants of the maternal Tdap group than in infants in the control group. No safety issues after maternal Tdap vaccination were encountered., Interpretation: In view of the high pertussis toxin antibody concentrations at age 3 months, maternal vaccination supports a delay of the first pertussis vaccination in infants until at least age 3 months. Maternal antibody interference affects antibody concentrations after primary and booster vaccinations. The clinical consequences of this interference remain to be established., Funding: The Dutch Ministry of Health, Welfare, and Sport., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
43. Chickenpox: An update.
- Author
-
Lo Presti C, Curti C, Montana M, Bornet C, and Vanelle P
- Subjects
- Chickenpox Vaccine therapeutic use, Child, France epidemiology, Hospitalization economics, Hospitalization statistics & numerical data, Humans, Immunization Schedule, Measles-Mumps-Rubella Vaccine therapeutic use, United States epidemiology, Vaccination economics, Vaccination methods, Vaccination trends, Vaccines, Combined therapeutic use, Chickenpox complications, Chickenpox economics, Chickenpox epidemiology, Chickenpox prevention & control
- Abstract
Despite its benign characteristics, chickenpox is a childhood disease responsible for complications and deaths, particularly in the high-risk population. VariZIG
® , not commercialized in France, is a good alternative for seronegative individuals exposed to the virus and not eligible for vaccination. The efficacy of routine vaccination has been demonstrated with a decrease in chickenpox incidence and with the development of herd immunity. Over time, the protective antibody titer of vaccinated people decreases and can be maintained by two doses of the vaccine. A tetravalent measles-mumps-rubella-chickenpox vaccine, used in the United States, has a good tolerability in spite of the occurrence of fever and febrile seizures. Routine vaccination would contribute to make savings in France, by reducing direct and indirect costs of chickenpox., (Copyright © 2018 Elsevier Masson SAS. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
44. Infectious bronchitis virus gel vaccination: evaluation of Mass-like (B-48) and 793/B-like (1/96) vaccine kinetics after combined administration at 1 day of age.
- Author
-
Tucciarone CM, Franzo G, Bianco A, Berto G, Ramon G, Paulet P, Koutoulis KC, and Cecchinato M
- Subjects
- Animals, Coronavirus Infections prevention & control, Coronavirus Infections virology, Kinetics, Poultry Diseases virology, Vaccines, Combined therapeutic use, Chickens, Coronavirus Infections veterinary, Infectious bronchitis virus immunology, Poultry Diseases prevention & control, Vaccination veterinary, Viral Vaccines therapeutic use
- Abstract
Infectious bronchitis (IB) control has a strong impact on poultry farming, because of the necessary epidemiological knowledge for planning the best strategy, the optimal strain association, the priming and boosting interventions. Broiler farming is even more problematic given the short and intense productive cycle, which requires an early onset of protection against most of the infectious threats, possibly with limited respiratory post-vaccination reactions that would have a direct impact on the bird health and productivity. For this purpose, gel vaccination has been proposed as a new approach for infectious bronchitis virus (IBV) control and vaccine intake, kinetics and compatibility of combined strains administered by gel have been analyzed in this study. After gel vaccination with single and combined 1/96 and B-48 strains on 4 groups of commercial broilers, a 21-d-long experimental trial has been conducted to monitor the vaccine safety by clinical assessment and vaccine kinetics by strain-specific real-time RT-PCR on choanal cleft swabs. The vaccine strains administered by gel were safe and negligible respiratory signs were detected, even when combined. Vaccine titers were compared among groups and within the same group among a 10-bird pooled sample and 10 swabs from individually sampled birds. 1/96 strain early reached high titers in all animals, while B-48 presence was less constant even though it was detected in almost all birds before the trial end. The individual and pooled sample comparison revealed a partial overestimation of vaccine titers in the pooled samples and the loss of the prevalence data, although the trend portrayed by the pooled swabs closely followed the individual ones.
- Published
- 2018
- Full Text
- View/download PDF
45. Safety and efficacy of DTaP-IPV vaccine use in healthcare workers for prevention of pertussis.
- Author
-
Shimizu H, Seki K, Shiga K, Nakayama T, and Mori M
- Subjects
- Adult, Antibodies, Bacterial blood, Bordetella pertussis, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Humans, Infant, Infectious Disease Transmission, Professional-to-Patient prevention & control, Middle Aged, Pediatrics, Pertussis Toxin immunology, Poliovirus Vaccine, Inactivated adverse effects, Vaccines, Combined adverse effects, Vaccines, Combined therapeutic use, Young Adult, Diphtheria-Tetanus-acellular Pertussis Vaccines therapeutic use, Health Personnel, Poliovirus Vaccine, Inactivated therapeutic use, Whooping Cough prevention & control
- Abstract
Pertussis can be fatal for infants. The best way to prevent infant pertussis is to promote adult immunization. However, Tdap has not been licensed in Japan, so we investigated the effect and safety of the DTaP-IPV vaccine instead. The study examined 154 pediatric healthcare workers. Participants without effective levels of antibodies against pertussis toxin were given DTaP-IPV, reduced to 0.2 mL. In total, 48 of the 154 participants (31.2%) were seronegative for pertussis toxin. After vaccination of the seronegative participants, 40 of the 41 measured (97.5%) had acquired an effective response, and all 35 of those tested maintained a protective antibody level ten months after vaccination. Redness was observed in 14 of the 41 (34.1%) and soreness in 19 (46.3%). This study demonstrated that vaccination with reduced 0.2 mL DTaP-IPV successfully provided effective immunity. At least ten months after vaccination, all subjects maintained an adequate level of antibodies., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
46. Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines.
- Author
-
Itell HL, McGuire EP, Muresan P, Cunningham CK, McFarland EJ, Borkowsky W, Permar SR, and Fouda GG
- Subjects
- AIDS Vaccines therapeutic use, Child, Child, Preschool, Diphtheria-Tetanus-Pertussis Vaccine therapeutic use, Enzyme-Linked Immunosorbent Assay methods, Female, Haemophilus Vaccines therapeutic use, Hepatitis B Vaccines therapeutic use, Humans, Immunization Schedule, Infant, Male, Poliovirus Vaccine, Inactivated therapeutic use, Vaccines, Combined therapeutic use, Antibodies, Bacterial blood, Antibody Formation, High-Throughput Screening Assays methods, Vaccines therapeutic use
- Abstract
Because vaccine co-administration can affect elicited immune responses, it is important to evaluate new vaccines in the context of pre-existing vaccination schedules. This is particularly necessary for new pediatric vaccines, as the World Health Organization's infant immunization program already schedules several vaccines to be administered during the first months of life. To facilitate the assessment of inter-vaccine interference, we developed a pediatric vaccine multiplex assay (PVMA) to simultaneously measure antibodies against vaccines commonly administered to infants, including hepatitis B, Haemophilus influenzae type B, diphtheria, tetanus, pertussis, rubella, and respiratory syncytial virus (RSV). Comparison of antibody concentrations determined by enzyme-linked immunosorbent assays (ELISAs) and the PVMA demonstrated that the PVMA is highly sensitive, specific, reproducible, and accurate. Moreover, the PVMA requires half the time to assess a cohort compared to ELISAs, and only costs marginally more. Demonstrating the utility of the assay, we employed the PVMA to assess vaccine interference in the setting of a candidate vaccine, using the infant HIV vaccines from the completed Pediatric AIDS Clinical Trials Group (PACTG) protocols 230 and 326 as examples. There was no substantial difference in antibody concentrations between vaccine and placebo recipients, which suggests that HIV vaccination did not disrupt antibody responses elicited by routine pediatric vaccines. Thus, the PVMA is a reliable, high-throughput technique that requires minimal sample volume to measure multiple antibody concentrations concurrently, and is an efficient alternative to ELISAs for the measurement of vaccine-elicited antibody responses in large cohorts., (Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
47. New perspectives for hexavalent vaccines.
- Author
-
Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, Rodríguez-Tenreiro Sánchez C, and Martinón-Torres F
- Subjects
- Diphtheria-Tetanus-Pertussis Vaccine therapeutic use, Europe, Haemophilus Vaccines therapeutic use, Haemophilus influenzae type b immunology, Hepatitis B immunology, Hepatitis B prevention & control, Hepatitis B Vaccines therapeutic use, Humans, Poliovirus Vaccine, Inactivated therapeutic use, Vaccination methods, Vaccines, Combined therapeutic use
- Abstract
With the increase in the number of routine vaccinations the development of pentavalent and hexavalent combination vaccines fitting the routine vaccination schedules became a necessity. In this respect, Europe has taken the lead in comparison with other world regions, and routine vaccination with pentavalent and hexavalent combinations including DTPa, Hib, HepB and IPV has been on European vaccination programs for >15years. Since the marketing authorization of Hexavac® and Infanrix Hexa® in 2000, immunization schedules in most European countries have included hexavalent vaccines. In the last years, two new hexavalent vaccines have been licensed and commercialized worldwide. This paper presents a review of the pharmaceutical profiles of the three hexavalent vaccines currently available. In addition, we aim to review safety, co-administration, tolerability and other practical concerns of their use., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
48. Mixing is required for uniform reconstitution of filter-dried protein antigens in a single-injection vaccine formulation.
- Author
-
Thangsupanimitchai N and Edwards AD
- Subjects
- Diphtheria-Tetanus-Pertussis Vaccine immunology, Drug Compounding, Haemophilus Vaccines immunology, Vaccines, Combined chemistry, Vaccines, Combined therapeutic use, Adjuvants, Immunologic chemistry, Antigens immunology
- Abstract
Ambient temperature filter dried vaccine formulations have been proposed to simultaneously achieve thermostability and offer a ready-to-use immunisation device that combines reconstitution and injection. Vaccine concentration should be uniform at the point of injection, but the uniformity following direct reconstitution of filter-dried vaccines has not been reported. We present here a study of vaccine mixing and release following dissolution of filter-dried model protein and toxoid antigens within a single syringe, filter and needle unit. Release was better for filters made from glass than cellulose. Without additional mixing, uniformity was poor and only 41% of input protein was released from protein filter-dried onto glass fiber. In contrast, adding a simple glass bead and mixing by inversion, 100% release antigen solution was achieved, with uniform concentration at exit from the needle throughout a simulated injection. Adsorption onto alum adjuvant had no detectable effect on vaccine dissolution and mixing. The uniformity and yield of low doses of diphtheria and tetanus toxoid was also improved by mixing, albeit with a lower yield of 60-68%. We conclude that uniformity and mixing should be studied to ensure safety and efficacy of directly reconstituted filter-dried vaccine formulations., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
49. Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants: Results of an Open, Randomized Trial.
- Author
-
Merino Arribas JM, Carmona Martínez A, Horn M, Perez Porcuna XM, Otero Reigada MDC, Marès Bermúdez J, Centeno Malfaz F, Miranda M, Mendez M, Garcia Cabezas MA, Christoph W, Bleckmann G, Fischbach T, Kolhe D, Van der Wielen M, and Baine Y
- Subjects
- Antibodies, Viral blood, Diphtheria-Tetanus-Pertussis Vaccine adverse effects, Female, Haemophilus Vaccines adverse effects, Hepatitis B Vaccines adverse effects, Humans, Immunization Schedule, Immunization, Secondary, Infant, Male, Pneumococcal Vaccines adverse effects, Pneumococcal Vaccines therapeutic use, Poliovirus Vaccine, Inactivated adverse effects, Vaccines, Combined adverse effects, Vaccines, Combined therapeutic use, Antibodies, Bacterial blood, Diphtheria-Tetanus-Pertussis Vaccine therapeutic use, Haemophilus Vaccines therapeutic use, Hepatitis B Vaccines therapeutic use, Immunogenicity, Vaccine, Poliovirus Vaccine, Inactivated therapeutic use
- Abstract
Background: This study evaluated the immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus virus-Haemophilus influenzae type b vaccine (DTPa-HBV-IPV/Hib) and a 10-valent pneumococcal conjugate vaccine (PHiD-CV) coadministered with a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) in infants/toddlers., Methods: In this open, controlled, phase III study (NCT01144663), 2095 healthy infants were randomized (1:1:1:1) into 4 groups to receive MenACWY-TT at 2, 3, 4 and 12 months of age or MenACWY-TT, MenC-CRM197, or MenC-TT at 2, 4 and 12 months of age. All participants received PHiD-CV and DTPa-HBV-IPV/Hib at 2, 3, 4 and 12 months of age. Immunogenicity of DTPa-HBV-IPV/Hib was evaluated in exclusive randomized subsets of 25% of participants from each group postprimary, prebooster and postbooster vaccination, whereas immunogenicity of PHiD-CV was evaluated at all time points. Reactogenicity was evaluated on the total vaccinated cohorts during 8 days after each vaccination., Results: For each DTPa-HBV-IPV/Hib antigen, ≥97.2%, ≥76.5% and ≥97.9% of participants had seropositive/seroprotective levels 1 month postprimary vaccination, before the booster dose and 1 month postbooster, respectively. For each vaccine pneumococcal serotype, ≥74.0% of infants had antibody concentrations ≥0.35 μg/mL at 1 month postprimary vaccination, and robust increases in antibody geometric mean concentrations were observed from prebooster to postbooster. Redness was the most frequent solicited local symptom at the DTPa-HBV-IPV/Hib and PHiD-CV injection sites, reported after up to 47.7% and 57.0% of doses postprimary and postbooster vaccination, respectively., Conclusions: Primary and booster vaccinations of infants/toddlers with DTPa-HBV-IPV/Hib and PHiD-CV coadministered with MenACWY-TT were immunogenic with clinically acceptable reactogenicity profiles. These results support the coadministration of MenACWY-TT with routine childhood vaccines.
- Published
- 2018
- Full Text
- View/download PDF
50. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study.
- Author
-
Monge S, Hahné SJ, de Melker HE, Sanders EA, van der Ende A, and Knol MJ
- Subjects
- Case-Control Studies, Child, Preschool, Diphtheria prevention & control, Female, Haemophilus Infections prevention & control, Humans, Immunization Schedule, Infant, Infant, Newborn, Male, Netherlands, Tetanus prevention & control, Vaccines, Combined therapeutic use, Diphtheria drug therapy, Diphtheria-Tetanus-Pertussis Vaccine therapeutic use, Haemophilus Infections drug therapy, Haemophilus Vaccines therapeutic use, Haemophilus influenzae type b drug effects, Hepatitis B Vaccines therapeutic use, Poliovirus Vaccine, Inactivated therapeutic use, Tetanus drug therapy
- Abstract
Background: In 2016, an increase in invasive Haemophilus influenzae serotype b (Hib) disease was reported in the Netherlands in children younger than 5 years, which coincided with the introduction of the hexavalent diphtheria, tetanus, and acellular pertussis-hepatitis B virus-inactivated polio virus/Hib vaccine (DTPa-HBV-IPV/Hib) from 2011 onwards. We aimed to estimate the effectiveness of the hexavalent vaccine to assess whether this increase could be explained by decreasing effectiveness., Methods: We did a case-control study in the Netherlands. We selected patients with a Hib infection (cases) by use of the surveillance records of the Netherlands Reference Laboratory for Bacterial Meningitis (Amsterdam). Cases with a Hib infection that began from Jan 1, 2003, to Dec 31, 2016, and who were younger than age 5 years were included. Ten controls from the national vaccination register (Praeventis) were selected for each case, matched by date of birth. Vaccination status was ascertained by use of Praeventis, which details the vaccination records of children living in the Netherlands. The last recorded vaccine dose was used to classify the child as having received the hexavalent DTPa-HBV-IPV/Hib vaccine or a pentavalent vaccine (which excludes the hepatitis B virus component) or another vaccine. We estimated the effectiveness of these vaccines by use of conditional logistic regression., Findings: We included 159 (94%) of 170 cases reported and 1590 matched controls, who had a median age of 1·5 years (IQR 0·8-2·9). The remaining 11 cases could not be cross-matched with vaccination records from Praeventis. 91 (57%) of 159 cases had been vaccinated, compared with 1408 (89%) of 1590 controls. The overall vaccine effectiveness was 92·8% (95% CI 88·7-95·4), with no differences between the year of disease onset (p=0·9670). There were no differences conferred by type of vaccine given: vaccine effectiveness of the pentavalent and other vaccines was 91·8% (95% CI 86·1-95·1) versus 94·0% (89·0-96·8) for the hexavalent vaccine (OR 0·72, 95% CI 0·36-1·45; p=0·3591). Vaccine effectiveness was highest in children aged 1-2 years at disease onset (97·1-99·0%) and was lowest in children aged 3-4 years at disease onset (60·7-82·3%; p=0·0008)., Interpretation: Our results support the current vaccination programme, since Hib vaccine effectiveness has not decreased over time or by the introduction of the hexavalent DTPa-HBV-IPV/Hib vaccine. Vaccine effectiveness was high but waned with age. Alternative explanations for the increase in Hib disease therefore need to be assessed., Funding: Dutch Ministry of Health, Welfare and Sports., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.